Concordance Between Tissue and Liquid Biopsy: A Foundational Guide for Precision Oncology Research and Drug Development

Abstract

This article provides a comprehensive analysis of the concordance between tissue and liquid biopsy for genomic profiling in cancer. Tailored for researchers and drug development professionals, it explores the biological foundations of biopsy concordance, evaluates current methodologies and their clinical applications, addresses key challenges and optimization strategies, and reviews clinical validation data and comparative performance. Synthesizing evidence from recent large-scale studies and trials, the content aims to inform robust biomarker strategy, assay development, and the effective integration of dual biopsy modalities in translational and clinical research to advance precision oncology.

The Biological and Technical Basis of Biopsy Concordance

In the era of precision oncology, the ability to accurately detect genomic alterations is paramount for guiding effective tailored therapies. This process relies heavily on diagnostic tests, primarily tissue and liquid biopsies, whose performance is quantified by key statistical measures: sensitivity, specificity, and predictive values. Concordance—the detection of the same actionable genomic alteration in both tissue and liquid biopsies—has emerged as a critical indicator of test reliability and a significant predictor of patient outcomes. This guide provides an objective comparison of these biopsy modalities, framing their performance within the context of concordance research essential for researchers, scientists, and drug development professionals.

Statistical Fundamentals: Defining Performance Metrics

The evaluation of any diagnostic test, including genomic profiling, is grounded in a core set of statistical parameters. These metrics are derived from a 2x2 contingency table that cross-references the test's results with the true disease status, as determined by a gold standard [1].

The core relationships between these statistical concepts and their real-world implications for biopsy analysis can be visualized below.

• Sensitivity (True Positive Rate): The proportion of subjects who are actually positive for a genomic alteration and are correctly given a positive assignment by the test. It answers the question: "How well does this test identify real alterations when they are present?" [1]. Formula: Sensitivity = True Positives / (True Positives + False Negatives)

• Specificity (True Negative Rate): The proportion of subjects who are actually negative for a genomic alteration and are correctly given a negative assignment. It answers: "How well does this test rule out the alteration when it is absent?" [1]. Formula: Specificity = True Negatives / (True Negatives + False Positives)

• Positive Predictive Value (PPV): The probability that a subject with a positive test result truly has the genomic alteration of interest. Unlike sensitivity and specificity, PPV is heavily influenced by the prevalence of the alteration in the population [1] [2].

• Negative Predictive Value (NPV): The probability that a subject with a negative test result truly does not have the genomic alteration [1].

These metrics are intrinsically linked; often, increasing sensitivity leads to a decrease in specificity, and vice-versa. The chosen threshold for a test directly impacts this balance [1].

Concordance in Clinical Trials: Evidence and Outcomes

The ROME trial, a significant phase II multicenter study, provides robust data on the clinical impact of concordance. It enrolled 1,794 patients with advanced solid tumors and performed next-generation sequencing (NGS) on both tissue (FoundationOne CDx) and liquid (FoundationOne Liquid CDx) biopsies. A Molecular Tumor Board identified actionable alterations, leading to the randomization of 400 patients to receive either tailored therapy (TT) or standard-of-care (SoC) [3] [4].

Key Experimental Protocol from the ROME Trial

• Patient Population: Adults with advanced or metastatic solid tumors on their second or third line of treatment.
• Biopsy Methods: Paired tissue and liquid biopsies were collected from all participants.
• Sequencing Technology: NGS was performed using FDA-approved/compliant assays (FoundationOne CDx for tissue, FoundationOne Liquid CDx for liquid).
• Analysis Method: A centralized Molecular Tumor Board reviewed sequencing results to define actionable alterations and assign patients to concordant or discordant groups.
• Study Design: Patients with actionable alterations were randomized to receive TT or SoC, with outcomes tracked for overall survival (OS) and progression-free survival (PFS) [3] [4].

The trial results underscore the critical importance of concordance, revealing distinct patient subgroups and associated outcomes as shown in the following workflow.

The clinical outcomes from the ROME trial provide compelling evidence for the value of concordant findings, with survival data summarized in the table below.

Table 1: Survival Outcomes Based on Biopsy Concordance in the ROME Trial [3] [4]

Patient Group	Overall Survival (OS) - Months	Progression-Free Survival (PFS) - Months	Objective Response Rate (ORR) - TT vs SoC
Concordant (T+L)	11.05 (TT) vs. 7.70 (SoC)	4.93 (TT) vs. 2.80 (SoC)	20.0% vs. 11.8%
Discordant (Tissue-Only)	9.93	3.06	Not Reported
Discordant (Liquid-Only)	4.05	2.07	Not Reported

Direct Comparison of Liquid and Tissue Biopsy Performance

Beyond survival outcomes, liquid and tissue biopsies differ fundamentally in their technical and operational characteristics. The following table provides a side-by-side comparison of these two modalities.

Table 2: Functional and Operational Comparison of Liquid vs. Tissue Biopsy [5] [6] [7]

Characteristic	Liquid Biopsy	Tissue Biopsy
Invasiveness	Minimally invasive (blood draw)	Invasive surgical procedure
Turnaround Time (TAT)	Faster (e.g., 26.8 days faster in one study)	Slower due to complex processing [5]
Tumor Heterogeneity Capture	Captures a broader profile from multiple sites	Limited to the specific site sampled
Best Clinical Use Cases	Screening, monitoring treatment response, tracking metastasis	Initial diagnosis, tumor typing and subtyping
Sensitivity	Can be high (e.g., 94.8-100% concordance for guideline-recommended NSCLC biomarkers)	Variable; considered the benchmark but can miss heterogeneity [5]
Specificity	High for certain mutations	High for the sampled region
Key Challenges	Lower sensitivity for low-shedding tumors; limited ctDNA in blood	Risk of sampling error; not always feasible to repeat

The relationship between a test's threshold and its sensitivity/specificity is a fundamental principle. As illustrated by a study on Prostate-Specific Antigen (PSA) density, lowering the threshold for a positive test (e.g., from ≥0.08 ng/mL/cc to ≥0.05 ng/mL/cc) increases sensitivity but decreases specificity. Conversely, raising the threshold has the opposite effect [1].

A Toolkit for Concordance Research

For researchers designing studies in this field, key reagents and methodologies are critical for generating reproducible results. The following table details essential components of the research toolkit as used in recent high-impact studies.

Table 3: Essential Research Reagent Solutions for Biopsy Concordance Studies [3] [5] [6]

Reagent / Solution	Function / Application	Example from Literature
cfDNA Extraction Kits	Isolation of high-quality, fragmented cell-free DNA from blood plasma/serum for NGS.	Magnetic bead-based kits that maximize cfDNA recovery from less than 1 mL of plasma [7].
Next-Generation Sequencing (NGS) Panels	Comprehensive genomic profiling to identify actionable mutations from minimal input DNA.	FoundationOne CDx (tissue) and FoundationOne Liquid CDx (liquid biopsy) [3] [5].
Circulating Tumor Cell (CTC) Enrichment Kits	Isolation of rare CTCs from whole blood based on markers like EpCAM or physical properties.	FDA-cleared CellSearch system for prognostic monitoring in breast cancer [6].
PCR Purification Kits	Post-amplification clean-up to remove enzymes, salts, and short fragments for superior NGS data.	Used to increase the quality of DNA sequences prior to automated sequencing [7].

The pursuit of precision oncology is fundamentally linked to the accurate and reliable detection of genomic alterations. The evidence clearly demonstrates that neither liquid nor tissue biopsy is universally superior; instead, they are complementary modalities. The key statistical metrics of sensitivity, specificity, and predictive value provide the essential framework for evaluating their performance. Crucially, concordance between liquid and tissue biopsies serves as a powerful biomarker, identifying a patient population most likely to derive significant survival benefit from tailored therapies. For researchers and drug developers, a dual-biopsy approach, supported by robust experimental protocols and reagents, is emerging as the new standard for optimizing patient selection and advancing the field of personalized cancer treatment.

The emergence of precision oncology has made accurate genomic profiling a cornerstone of cancer therapy. However, the inherent biological complexity of tumors presents a significant challenge, often leading to discordant results between tissue and liquid biopsy modalities. This discordance is not merely a technical artifact but a reflection of fundamental biological processes: tumor heterogeneity, variable shedding rates, and continuous clonal evolution [8] [9]. For researchers and drug development professionals, understanding these sources of discrepancy is critical for optimizing diagnostic strategies, interpreting genomic data, and designing effective targeted therapies. This guide objectively compares the performance of tissue and liquid biopsy in capturing the tumor genome, supported by experimental data that illuminates the biological underpinnings of their discordance.

Quantitative Analysis of Discordance

Clinical studies directly comparing tissue and liquid biopsy reveal a measurable rate of discordance in the detection of actionable biomarkers. The following table synthesizes key quantitative findings from recent research.

Table 1: Concordance Rates for Actionable Biomarkers Between Tissue and Liquid Biopsy

Cancer Type	Biomarker	Concordance Rate	Notes	Source Study
NSCLC (Real-world)	EGFR Mutations	94.5%	Positive Predictive Value: 100%; Negative Predictive Value: 95%	CLEAR Study [10]
Pan-Cancer (ROME Trial)	Various Actionable Alterations	49.2% (Concordant)	34.7% tissue-only; 16.0% liquid-only	ROME Trial [4]
NSCLC (Multi-center)	Guideline-Recommended Biomakers	94.8% - 100%	High concordance for specific actionable genes	Raez et al. [5]

The ROME trial, a significant phase II study, further demonstrated that the clinical impact of discordance is profound. Patients whose tailored therapy was guided by concordant findings in both tissue and liquid biopsy (the T+L group) experienced significantly improved outcomes compared to those receiving standard of care, with a median overall survival of 11.05 months vs. 7.7 months and a 45% reduction in the risk of progression [4]. In contrast, the survival benefit from tailored therapy was less pronounced or absent when based on discordant results, underscoring the biological and clinical significance of these findings.

Table 2: Clinical Outcomes Based on Biopsy Concordance in the ROME Trial

Patient Group	Median Overall Survival (Months)	Median Progression-Free Survival (Months)	12-Month Overall Survival Rate
T+L Group (Tailored Therapy)	11.05	4.93	47.8%
T+L Group (Standard of Care)	7.7	2.8	38.8%
Tissue-Only Group	9.93	3.06	Not Reported
Liquid-Only Group	4.05	2.07	Not Reported

Biological Mechanisms of Discordance

The quantitative discordance between biopsy modalities stems from specific biological phenomena. The following experimental data and mechanistic insights outline the core sources.

Tumor Heterogeneity

Intratumor heterogeneity fosters tumor evolution and is a key challenge in cancer medicine [9]. The "Cancer Stem Cell (CSC) hypothesis" posits that only a minority fraction of cancer cells, the Tumor Initiating Cells (TICs), can initiate tumors and give rise to a hierarchical population of more differentiated cells [8]. A single tissue biopsy, taken from one spatial location, may miss critical mutations present in other regions of the tumor or in metastatic sites [4]. In contrast, liquid biopsy, which captures ctDNA shed from multiple tumor sites, can provide a more comprehensive "average" of the tumor genome, though it may fail to detect clones residing in poorly vascularized niches [8] [11].

Diagram 1: Spatial Heterogeneity & Sampling Bias. A single tissue sample captures only a localized subclone, while a liquid biopsy integrates DNA from multiple clones, provided they shed into the bloodstream.

Variable ctDNA Shedding

The presence and concentration of circulating tumor DNA (ctDNA) in the bloodstream is not uniform. It depends on factors such as tumor burden, location, vascularity, and cellular turnover [11] [12]. Tumors with low metabolic activity or those that are poorly vascularized may shed very little DNA, leading to false-negative results in liquid biopsy [4] [11]. For instance, one study noted that while 47% of patients with skin or lymph node metastases had detectable ctDNA, the rate was only 40% for those with lung metastases, indicating that the metastatic site influences shedding [12]. This biological limitation means that a negative liquid biopsy cannot definitively rule out the presence of disease.

Clonal Evolution

Tumors are not static; they dynamically evolve over time and in response to therapeutic pressures [8] [9]. This process, known as clonal evolution, can lead to temporal discordance between biopsies. A tissue biopsy taken at diagnosis may not reflect the genetic landscape of the tumor at relapse or after treatment has selected for resistant clones [8]. Liquid biopsy, with its ease of serial sampling, is better suited to monitor this dynamic process and identify emerging resistance mutations [11] [12]. This represents a key application where liquid biopsy outperforms single-shot tissue profiling.

Diagram 2: Temporal Evolution & Therapy Pressure. A tissue biopsy at diagnosis captures the pre-treatment heterogeneity. Therapy selectively kills sensitive clones, allowing a resistant clone to dominate at relapse, a change detectable by serial liquid biopsy.

Experimental Protocols for Studying Discordance

To systematically investigate the sources of discordance, researchers employ rigorous experimental workflows. The following protocols are foundational to this field.

Dual-Modality Biopsy Profiling

Objective: To directly compare the genomic alterations detected by tissue and liquid biopsy in the same patient and assess concordance.

Methodology:

• Concurrent Sample Collection: Tissue and blood samples are collected from a patient with advanced cancer as close in time as possible to minimize temporal evolution as a confounder [4] [5].
• Nucleic Acid Extraction:
  • Tissue: DNA is extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections. Macro-dissection or micro-dissection may be used to enrich for tumor content [4].
  • Liquid: Plasma is separated from blood via centrifugation. Cell-free DNA (cfDNA) is extracted from the plasma, and circulating tumor DNA (ctDNA) is a fraction of this cfDNA [11] [12].
• Next-Generation Sequencing (NGS): Both tissue DNA and plasma cfDNA are analyzed using targeted, whole-exome, or whole-genome NGS panels. High-depth sequencing (>500x-1000x) is often used for cfDNA to detect low-frequency mutations [4] [5] [10].
• Bioinformatic Analysis: Sequencing data is processed through pipelines for alignment, variant calling, and annotation. Specific algorithms are used to call low-allele-frequency variants from the cfDNA data while controlling for sequencing errors and clonal hematopoiesis.
• Concordance Assessment: Detected alterations, especially in actionable genes, are classified as:
  • Concordant: Found in both tissue and liquid.
  • Tissue-only: Found only in tissue.
  • Liquid-only: Found only in liquid [4].

Circulating Tumor Cell (CTC) Enumeration & Characterization

Objective: To correlate tumor burden and phenotypic heterogeneity with biopsy discordance.

Methodology:

• CTC Enrichment: Blood samples are processed using enrichment techniques. The FDA-cleared CELLSEARCH system uses immunomagnetic capture with anti-EpCAM (Epithelial Cell Adhesion Molecule) antibodies. Other methods include size-based filtration (ISET) or depletion of CD45-positive white blood cells [11].
• CTC Identification: Enriched cells are stained with fluorescent antibodies:
  • DAPI (nuclear stain).
  • Anti-cytokeratin (CK) (epithelial marker, positive in CTCs).
  • Anti-CD45 (leukocyte marker, negative in CTCs). CTCs are defined as DAPI+/CK+/CD45- [11].
• Downstream Analysis: Isolated CTCs can be subjected to:
  • Immunofluorescence: For protein expression analysis.
  • Single-Cell Sequencing: To analyze genomic heterogeneity at the single-cell level and compare with bulk tissue and ctDNA profiles.
  • Culture: For functional studies and drug sensitivity testing [11].

The Scientist's Toolkit: Research Reagent Solutions

Successfully navigating the complexities of biopsy discordance requires a suite of specialized reagents and tools. The following table details essential materials for research in this field.

Table 3: Essential Research Reagents and Tools for Discordance Studies

Item	Function/Application	Example Use Case
FoundationOne CDx	Comprehensive genomic profiling platform for tissue samples.	Interrogates 324+ genes, TMB, and MSI from FFPE tissue; used as the tissue comparator in the ROME trial [4].
FoundationOne Liquid CDx	Comprehensive genomic profiling platform for liquid biopsies.	Analyzes 311+ genes, TMB, and MSI from blood-derived cfDNA; used as the liquid comparator in the ROME trial [4].
CELLSEARCH System	FDA-cleared, automated system for CTC enumeration.	Isolates and counts CTCs from whole blood using anti-EpCAM immunomagnetic capture; used for prognostic studies in SCLC and other cancers [11].
Anti-EpCAM Antibodies	Immunomagnetic capture of epithelial-derived CTCs.	Key component of the CELLSEARCH system and other microfluidic CTC capture devices [11].
Anti-CD45 Antibodies	Negative selection to deplete leukocytes during CTC enrichment.	Used in "leukocyte depletion" strategies to improve CTC purity for downstream analysis [11].
Droplet Digital PCR (ddPCR)	Ultrasensitive, absolute quantification of specific DNA mutations.	Used for validating low-frequency mutations found in ctDNA and for monitoring MRD with high sensitivity [11] [12].
Cobas cfDNA Sample Preparation Kit	Standardized extraction and preparation of cell-free DNA from plasma.	Used in the CLEAR study to prepare samples for EGFR mutation testing, ensuring consistent input material for analysis [10].

The biological discordance between tissue and liquid biopsies is not a flaw in the technologies, but a window into the complex realities of cancer biology. Spatial heterogeneity, dynamic clonal evolution, and variable ctDNA shedding are fundamental properties of tumors that directly impact diagnostic accuracy and clinical decision-making. The experimental data presented confirms that neither modality is universally superior; rather, they offer complementary views. The most robust approach for precision oncology is a combined one, leveraging the depth of tissue information with the breadth and serial accessibility of liquid biopsy. Future research must focus on improving the sensitivity of liquid biopsy for low-shedding tumors, developing bioinformatic tools to better deconvolute heterogeneous signals, and standardizing integrated testing protocols to fully harness the synergistic potential of both methods for drug development and patient care.

Liquid biopsy has emerged as a transformative approach in cancer management, providing a minimally invasive window into tumor dynamics through the analysis of circulating biomarkers. In the context of advancing research on concordance between tissue and liquid biopsy results, three biomarkers stand out for their complementary clinical value: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs). While tissue biopsy remains the gold standard for tumor diagnosis and molecular profiling, its limitations—including invasiveness, inability to capture full tumor heterogeneity, and impracticality for serial monitoring—have driven the exploration of liquid-based alternatives [6]. These circulating biomarkers originate from primary tumors or metastatic sites and carry molecular information that reflects the tumor's genetic and phenotypic landscape [13]. The concordance between tissue and liquid biopsy findings has become a critical research focus, with studies demonstrating that combining both modalities significantly increases the detection of actionable alterations and improves patient outcomes [14]. This comparison guide examines the technical specifications, clinical applications, and methodological considerations for these three key biomarkers to inform researchers, scientists, and drug development professionals.

Biomarker Fundamentals and Technical Characteristics

Biological Origins and Analytical Targets

The three biomarkers originate through distinct biological processes and offer different analytical opportunities. ctDNA consists of short DNA fragments (typically 160-200 base pairs) released into the bloodstream primarily through tumor cell apoptosis and necrosis [6] [15]. These fragments carry tumor-specific genetic and epigenetic alterations, including mutations, copy number variations, and methylation patterns [13]. CTCs are intact, viable tumor cells that detach from primary or metastatic sites and enter the circulation, capable of seeding new metastases [16] [17]. They represent a rare cell population amidst blood cells, with approximately only 1 CTC per 1 million leukocytes [6]. EVs are lipid-bilayer-enclosed nanoparticles released by cells through various biogenesis pathways, including exosomes, microvesicles, and apoptotic bodies [18]. They carry molecular cargo from their parent cells—including DNA, RNA, proteins, lipids, and metabolites—and play functional roles in cell-cell communication and driving malignant behaviors [13].

Technical Comparison of Key Biomarkers

Table 1: Comparative analysis of key liquid biopsy biomarkers

Parameter	ctDNA	CTCs	Extracellular Vesicles (EVs)
Biological Origin	Apoptosis/necrosis of tumor cells [6]	Cells shed from primary or metastatic tumors [16]	Secreted by cells through exocytosis, budding, or apoptosis [18]
Analytical Targets	Mutations, copy number variations, methylation patterns [13] [6]	Whole cells for genomic, transcriptomic, proteomic analysis [13] [16]	DNA, RNA (miRNA, mRNA), proteins, lipids [13] [18]
Approximate Abundance in Blood	0.01-90% of total cell-free DNA [6] [15]	0-100 cells per mL of blood [17]	<0.1% tumor-derived EVs in total EV population [19]
Half-Life	15 minutes to 2.5 hours [15]	1-2.5 hours [6]	Varies; generally stable [18]
Key Isolation Principles	Blood collection tubes with cell stabilizers, double centrifugation, solid-phase extraction [20]	Immunomagnetic separation (EpCAM/CK), size-based filtration, microfluidics [13] [17]	Ultracentrifugation, size-exclusion chromatography, immunoaffinity capture [18]
Primary Detection Methods	ddPCR, NGS, BEAMing [13] [14]	Immunofluorescence, CellSearch, Parsortix, FISH [13] [15]	NTA, Western blot, ELISA, DPCR [18]
FDA-Approved Platforms	Guardant360 CDx, FoundationOne Liquid CDx [15]	CellSearch System [13] [17]	None currently [18]

Complementary Relationship in Clinical Application

The diagram below illustrates how these three biomarkers provide complementary information through different biological pathways and timeframes, collectively enabling a more comprehensive understanding of tumor biology than any single biomarker alone.

Methodological Approaches and Experimental Protocols

Sample Collection and Pre-analytical Processing

Proper sample collection and processing are critical for reliable liquid biopsy results. For blood-based assays, recommendations include using butterfly needles to avoid cell damage, collecting 2×10 mL of blood for single-analyte tests, and employing specialized blood collection tubes (BCTs) with cell-stabilizing preservatives for ctDNA analysis [20]. EDTA tubes require fast processing within 2-6 hours at 4°C, while specialized BCTs (e.g., Streck cfDNA, PAXgene Blood ccfDNA) allow sample storage for up to 7 days at room temperature [20]. Plasma separation typically involves double centrifugation: an initial slow spin (380-3,000 g for 10 minutes at room temperature) to remove cells, followed by a high-speed spin (12,000-20,000 g for 10 minutes at 4°C) to eliminate remaining debris and platelets [20]. For CTC analysis, rapid processing is essential due to their short half-life, with methods often requiring cell stabilization to preserve viability and surface epitopes [13] [17]. EV isolation requires careful handling to prevent vesicle disruption, with protocols varying based on the intended downstream analysis [18] [19].

Biomarker-Specific Isolation and Enrichment Protocols

Table 2: Comparison of isolation methodologies across the three biomarker classes

Biomarker	Isolation Technique	Principles	Protocol Details	Advantages	Limitations
CTCs	Immunomagnetic Separation (CellSearch)	Antibody-coated magnetic beads target epithelial markers (EpCAM, CK) [13] [17]	Blood sample incubated with anti-EpCAM magnetic beads; magnetic separation of bound cells; immunofluorescence staining for identification [13] [15]	FDA-approved; standardized; high specificity for epithelial CTCs	Misses EpCAM-negative CTCs (especially EMT phenotypes) [17]
	Size-Based Filtration (Parsortix)	Captures cells based on size and deformability [15]	Blood pumped through microfluidic cassette with precise gap size (6-8 μm); CTCs trapped while blood cells pass [15]	Label-free; preserves cell viability; enables downstream molecular analysis	May miss smaller CTCs; purity challenges [13]
ctDNA	Solid-Phase Extraction	DNA binding to silica membranes or magnetic beads in high-salt conditions [20]	Plasma incubated with binding buffer; transferred to silica columns or magnetic beads; washing; elution in low-salt buffer [20]	High yield; suitable for automation; compatible with downstream applications	Inefficient for very short fragments
EVs	Ultracentrifugation	Sequential centrifugation at increasing speeds up to 100,000+ g [18]	300 g (10 min) → 2,000 g (10 min) → 10,000 g (30 min) → 100,000 g (70 min); pellets resuspended in buffer [18]	Gold standard; high purity; no specialized reagents	Time-consuming; equipment-intensive; may damage EVs
	Size-Exclusion Chromatography	Separation by hydrodynamic radius using porous beads [18]	Sample applied to column; fractions collected; EVs elute in early fractions before soluble proteins	Good preservation of EV integrity and function	Diluted samples; may co-isolate similar-sized particles

Detection and Analytical Workflows

The experimental workflow for liquid biopsy analysis involves multiple steps from sample collection to data interpretation, with both shared and biomarker-specific procedures.

For CTC detection and analysis, the CellSearch system represents the FDA-approved standard for metastatic breast, prostate, and colorectal cancers. This automated system uses EpCAM-based immunomagnetic enrichment followed by immunofluorescence staining with cytokeratin (CK) antibodies, CD45 (leukocyte marker), and DAPI (nuclear stain) for identification [13] [17]. CTC enumeration provides prognostic information, with specific thresholds (e.g., ≥5 CTCs/7.5 mL blood in metastatic breast cancer) associated with poorer survival [6]. Downstream molecular analysis may include single-cell sequencing, fluorescence in situ hybridization (FISH), or protein profiling to assess therapeutic targets and heterogeneity [16] [17].

ctDNA analysis primarily utilizes amplification-based methods including droplet digital PCR (ddPCR) and next-generation sequencing (NGS). ddPCR provides ultra-sensitive detection of known mutations, with applications in monitoring minimal residual disease (MRD) and tracking resistance mutations [14] [15]. NGS-based approaches include targeted panels (Guardant360, FoundationOne Liquid CDx) for comprehensive genomic profiling, whole-genome sequencing for copy number and fragmentation analysis, and epigenomic methods for methylation patterning [14] [15]. The Signatera test represents a personalized approach for MRD detection, using patient-specific mutations identified in tumor tissue to create custom ctDNA assays [15].

EV analysis employs a combination of physical characterization and molecular profiling. Nanoparticle tracking analysis (NTA) determines EV size distribution and concentration, while transmission electron microscopy provides morphological information [18] [19]. Western blotting confirms the presence of EV marker proteins (e.g., CD9, CD63, CD81), and enzyme-linked immunosorbent assays (ELISAs) enable quantification of specific EV-associated antigens [18]. For content analysis, RNA and protein extraction from EV preparations followed by sequencing or proteomic profiling can reveal tumor-derived molecular signatures [13] [18].

Clinical Applications and Performance Data

Diagnostic, Prognostic, and Predictive Utility

Each biomarker demonstrates distinct strengths across the cancer care continuum. ctDNA excels in early cancer detection and molecular profiling, with multi-cancer early detection (MCED) tests achieving specificities of 98.5% and overall sensitivities of 59.7% (increasing to 84.2% in late-stage tumors) [14]. In non-small cell lung cancer, plasma ctDNA testing can identify EGFR mutations with high concordance to tissue testing, guiding targeted therapy selection [6]. CTC enumeration provides robust prognostic information across multiple cancer types, with baseline counts independently predicting overall survival and progression-free survival in metastatic breast, prostate, and colorectal cancers [6] [17]. Emerging data also suggest that phenotypic and molecular characterization of CTCs can predict treatment resistance, such as AR-V7 expression in prostate cancer indicating resistance to androgen receptor-targeted therapies [16]. EVs show promise in early detection, with EV-associated miRNAs and proteins demonstrating diagnostic potential in hepatocellular carcinoma, colorectal cancer, and ovarian cancer [13] [18]. In neuroblastoma, plasma EV concentration and nucleolin expression were higher in high-risk patients, suggesting prognostic utility [14].

Therapy Monitoring and Minimal Residual Disease Detection

Serial monitoring of ctDNA dynamics provides a sensitive approach for assessing treatment response and detecting minimal residual disease (MRD). In the VICTORI study on colorectal cancer, 87% of recurrences were preceded by ctDNA positivity, while no ctDNA-negative patients relapsed [14]. Similarly, in bladder cancer, the TOMBOLA trial demonstrated high concordance (82.9%) between ddPCR and whole-genome sequencing for ctDNA detection, with both methods providing lead time over imaging for recurrence identification [14]. CTC monitoring also offers value in treatment response assessment, with changes in CTC counts correlating with therapeutic efficacy in metastatic cancers [16] [17]. The morphological evaluation of chromosomal instability in CTCs (CTC-CIN) has shown predictive value for taxane resistance in metastatic prostate cancer [14]. EV-based monitoring is an emerging application, with studies suggesting that changes in EV cargo may reflect treatment response and emerging resistance mechanisms [18].

Concordance with Tissue Biopsy

The concordance between liquid and tissue biopsy has been extensively studied, particularly for ctDNA. Combined tissue and liquid biopsy approaches in the ROME trial demonstrated that although concordance for actionable alterations was only 49%, the combination significantly increased overall detection and led to improved survival outcomes [14]. Discordant results may reflect technical limitations but also true biological differences, including tumor heterogeneity and the representation of distinct tumor subclones in circulation versus the primary tissue [17]. Spatial and temporal heterogeneity contributes to discordance, as liquid biopsy captures contributions from multiple tumor sites (including undetected metastases) and represents real-time tumor dynamics, while tissue biopsy provides a static snapshot of a single anatomic location [17].

Essential Research Reagents and Platforms

The Scientist's Toolkit: Key Research Reagent Solutions

Table 3: Essential research reagents and platforms for liquid biopsy analysis

Category	Product/Platform	Specific Application	Key Features
Blood Collection & Stabilization	Cell-Free DNA BCT (Streck)	ctDNA stabilization	Preserves cell integrity, prevents gDNA release, enables room temp transport for up to 7 days [20]
	PAXgene Blood ccfDNA Tubes (Qiagen)	ctDNA stabilization	Contains preservatives for nucleated blood cells, maintains sample quality [20]
Nucleic Acid Extraction	QIAamp Circulating Nucleic Acid Kit (Qiagen)	ctDNA/EV RNA extraction	Silica-membrane technology, high sensitivity for low-abundance targets [20]
	Cobas cfDNA Sample Preparation Kit (Roche)	ctDNA extraction	Optimized for downstream mutation detection, compatible with PCR/NGS [20]
CTC Isolation & Analysis	CellSearch System (Menarini)	CTC enumeration	FDA-approved, EpCAM-based immunomagnetic capture, standardized enumeration [13] [17]
	Parsortix PC1 System (Angle plc)	CTC isolation	Size-based microfluidic capture, preserves cell viability, enables molecular analysis [15]
ctDNA Analysis	Guardant360 CDx (Guardant Health)	ctDNA sequencing	FDA-approved, 73-gene NGS panel, detects SNVs, indels, fusions, CNAs [15]
	FoundationOne Liquid CDx (Foundation Medicine)	ctDNA sequencing	FDA-approved, 300+ gene panel, comprehensive genomic profiling [15]
	Signatera Test (Natera)	MRD monitoring	Personalized, tumor-informed assay, tracks 16 patient-specific mutations [15]
EV Isolation & Characterization	ExoQuick (System Biosciences)	EV precipitation	Polymer-based precipitation, suitable for small volumes, moderate purity [18]
	qEV Size Exclusion Columns (Izon Science)	EV purification	Size-based separation, preserves vesicle integrity, good recovery [18]

Current Challenges and Future Directions

Despite significant advances, several challenges remain in the clinical implementation of liquid biopsy biomarkers. Sensitivity limitations persist particularly in early-stage disease and low tumor burden settings, with ctDNA fractions often below 0.1% in stage I/II cancers [20] [6]. Technical standardization is lacking across platforms, with variations in pre-analytical processing, analysis methods, and interpretation criteria complicating cross-study comparisons and clinical adoption [20] [17]. For CTCs, isolation efficiency remains challenged by phenotypic heterogeneity, particularly the detection of EpCAM-negative cells undergoing epithelial-to-mesenchymal transition [16] [17]. EV analysis faces challenges in separating tumor-derived EVs from abundant background vesicles, with tumor EVs estimated to represent less than 0.1% of total EVs in blood [19]. Additionally, the biological complexity of EV cargo and standardization of isolation methods present significant hurdles [18] [19].

Future directions include the development of multi-analyte approaches that combine information from ctDNA, CTCs, and EVs to provide a more comprehensive tumor profile [17]. Technological innovations such as the MUTE-Seq method for ultrasensitive mutation detection and single-EV analysis platforms are addressing sensitivity limitations [14] [19]. Large-scale clinical validation studies are ongoing to establish standardized protocols and demonstrate clinical utility across diverse cancer types and stages [14] [6]. The integration of artificial intelligence and machine learning approaches for data analysis is poised to enhance the interpretation of complex liquid biopsy data [18]. As evidence accumulates, these biomarkers are increasingly positioned to complement tissue biopsy across the cancer care continuum, from early detection to monitoring treatment response and guiding therapeutic decisions.

The evolution of precision oncology has increasingly relied on comprehensive genomic profiling to guide therapeutic decisions. For years, tissue biopsy has been the gold standard for obtaining tumor DNA for analysis. However, the emergence of liquid biopsy, which analyzes circulating tumor DNA (ctDNA) from blood samples, presents a less invasive alternative with the potential to capture tumor heterogeneity more fully. A critical question remains: how concordant are the results from these two methodologies? Establishing baseline concordance rates is fundamental to developing integrated diagnostic strategies that maximize the detection of actionable alterations. Recent landmark studies provide the first robust, large-scale data addressing this question, revealing both significant discordance and a powerful synergistic relationship when both modalities are combined.

Key Findings: Concordance Rates and Clinical Impact

The phase II ROME trial, a pivotal multicenter study presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, offers the most comprehensive data on concordance rates and their direct clinical implications [4] [21].

The ROME trial enrolled 1,794 patients with advanced solid tumors who had undergone both tissue and liquid biopsy. Centralized next-generation sequencing was performed, and a molecular tumor board identified 400 patients with actionable alterations [21].

The table below summarizes the detection rates and concordance of actionable alterations from the ROME trial:

Detection Category	Percentage of Patients	Description
Overall Concordance	49.2% (197/400) [4]	The same actionable genomic alteration was identified in both the tissue and liquid biopsy.
Tissue-Only Detection	34.7% (139/400) [4]	Actionable alterations were detected exclusively in the tissue biopsy.
Liquid-Only Detection	16.0% (64/400) [4]	Actionable alterations were detected exclusively in the liquid biopsy.
Overall Actionable Alteration Detection	>60% [21]	The combined use of both biopsy types increased the detection of actionable alterations beyond what either method could achieve alone.

Survival Outcomes by Biopsy Concordance

The clinical power of concordance was demonstrated by analyzing survival outcomes for patients receiving tailored therapy versus standard of care (SOC) [4] [21].

The following table compares the survival outcomes based on biopsy results and treatment type:

Biopsy Group & Treatment	Median Overall Survival (Months)	Median Progression-Free Survival (Months)
T+L Concordant / Tailored Therapy	11.05	4.93
T+L Concordant / Standard of Care	7.7	2.8
Tissue-Only / Tailored Therapy	9.93	3.06
Liquid-Only / Tailored Therapy	4.05	2.07

Patients in the T+L concordant group who received tailored therapy had the best outcomes, with a 26% reduction in the risk of death and a 45% reduction in the risk of progression compared to SOC [4]. This suggests that concordance between biopsies may identify a patient population with a more consistent targetable alteration across metastatic sites, leading to superior response to matched therapy.

Experimental Protocols

Understanding the methodology of landmark studies like ROME is crucial for interpreting their findings and designing future research.

ROME Trial Design and Workflow

The ROME trial (NCT04591431) was a prospective, multicenter, phase II study designed to assess the clinical utility of combined tissue and liquid biopsy profiling [4] [21].

1. Patient Enrollment:

• Cohort: 1,794 adult patients with advanced or metastatic solid tumors.
• Line of Therapy: Patients were on their second or third line of systemic treatment [4] [21].

2. Sample Collection and Processing:

• Tissue Biopsy: Archived or newly obtained formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were analyzed using the FoundationOne CDx test [21].
• Liquid Biopsy: Blood samples were collected for plasma isolation and analyzed using the FoundationOne Liquid CDx test [21].
• Both tests are comprehensive genomic profiling assays that use next-generation sequencing (NGS) to identify actionable alterations.

3. Centralized Analysis and Actionability Assessment:

• Sequencing data from both biopsy types for each patient were reviewed by a centralized molecular tumor board.
• The board identified "actionable" genomic alterations—those with potential to be targeted by an approved or investigational tailored therapy.
• Patients were then categorized based on whether the actionable alteration was found in both biopsies (concordant) or only in one (discordant) [4] [21].

4. Treatment Assignment and Endpoints:

• Within each molecular group (T+L, Tissue-Only, Liquid-Only), patients were randomly assigned to receive either tailored therapy (matched to the genomic alteration) or clinician's choice of standard of care.
• The primary endpoints were Overall Survival (OS) and Progression-Free Survival (PFS), comparing tailored therapy to SOC within and across the molecular groups [4].

ROME Trial Workflow: From patient enrollment to survival analysis

Analysis of Discordance

The ROME trial also provided a detailed breakdown of the reasons for discordant results (203 cases) between tissue and liquid biopsies [21]:

• 43.3% were due to differences in the detection of specific molecular alterations.
• 35% were attributed to discordance in the measurement of high tumor mutational burden (TMB).
• 1% were due to discrepancies in microsatellite instability (MSI) status.
• 21% were due to test failures in one of the two platforms.

The study noted that the PI3K/PTEN/AKT/mTOR and ERBB2 pathways exhibited the highest rates of discordance [21].

Discordance Analysis: Breakdown of causes and affected pathways

The Scientist's Toolkit: Research Reagent Solutions

The experiments cited in this guide rely on specific, validated commercial platforms and reagents. The following table details key solutions essential for conducting similar concordance research.

Research Tool	Specific Product/Assay	Primary Function in Concordance Research
Comprehensive Genomic Profiling (Tissue)	FoundationOne CDx [21]	A next-generation sequencing (NGS)-based in vitro diagnostic test that uses FFPE tumor tissue to identify substitutions, insertion and deletion alterations, and copy number alterations (CNAs) in 324 genes, as well as genomic signatures like TMB and MSI.
Comprehensive Genomic Profiling (Liquid)	FoundationOne Liquid CDx [21]	An NGS-based in vitro diagnostic test that uses a blood sample to analyze ctDNA for genomic alterations in 311 genes, including TMB, MSI, and tumor fraction. Serves as the direct comparator to tissue-based profiling.
Programmed Death-Ligand 1 (PD-L1) IHC Assays	Clones 22C3, 28-8, SP263, SP142 [22] [23]	A panel of FDA-approved immunohistochemistry (IHC) assays used to assess PD-L1 expression on tumor cells and/or immune cells. Used to evaluate analytical concordance between different diagnostic antibodies, which informs on biomarker interchangeability.
RNA In Situ Hybridization Assay	RNAscope with PD-L1 (CD274) probe [23]	A method for detecting PD-L1 RNA transcripts within tumor tissue. Used as a complementary validation tool to confirm protein expression results from IHC and assess the concordance between RNA and protein-level detection.

Landmark studies like the ROME trial provide a critical baseline, demonstrating that tissue and liquid biopsies are not interchangeable but are powerfully complementary. The approximately 50% concordance rate for actionable alterations underscores the significant biological and technical discordance that exists. Crucially, this discordance means that relying on a single biopsy modality fails to identify a substantial proportion of patients who could benefit from tailored therapy. The superior survival outcomes observed when tailored treatment is guided by concordant findings in both biopsies establish a new paradigm for precision oncology. For researchers and drug developers, these findings advocate for diagnostic strategies that integrate both tissue and liquid biopsies to fully capture a tumor's genomic landscape, optimize patient selection for targeted therapies, and ultimately improve clinical trial success and patient outcomes.

Methodologies and Clinical Applications in Profiling and Monitoring

Next-Generation Sequencing (NGS) Platforms for Tissue and Liquid Biopsy

The paradigm of cancer management has shifted towards precision medicine, necessitating comprehensive genomic profiling to guide targeted therapies. Next-Generation Sequencing (NGS) has emerged as the cornerstone technology for this profiling, applicable to both traditional tissue biopsies and the increasingly adopted liquid biopsies. The central thesis framing this technological comparison concerns the concordance between tissue and liquid biopsy results—a critical factor determining their clinical and research utility. Tissue biopsy remains the diagnostic gold standard but faces limitations including invasiveness, sampling bias due to tumor heterogeneity, and impracticality for serial monitoring [24] [25]. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) from blood, offers a minimally invasive alternative that captures a broader spatial and temporal representation of the tumor genome [26] [27]. Evaluating NGS platforms for these two sample types requires a focus on their diagnostic performance, technical capabilities, and the degree to which their results align, thereby enabling confident application in research and drug development.

Performance Comparison: Diagnostic Accuracy and Concordance

The clinical validity of NGS testing, whether on tissue or liquid biopsy, is established through metrics of diagnostic accuracy and their mutual concordance. A large systematic review and meta-analysis demonstrated that liquid biopsy NGS assays exhibit a pooled sensitivity of 0.78 (95% CI: 0.72-0.83) and a high specificity of 0.93 (95% CI: 0.89-0.96) when compared to tissue biopsy [24]. This high specificity indicates that a positive finding from a liquid biopsy is highly reliable, while the moderate sensitivity suggests that a negative result may not always rule out a mutation present in the tissue.

Mutation-Specific Concordance and Detection Rates

The concordance between tissue and plasma NGS is not uniform across all genetic alteration types. It is generally highest for single nucleotide variants (SNVs) and insertions/deletions (indels), and lower for structural variants like fusions or copy number variations (CNVs) [28].

Table 1: Mutation-Specific Concordance and Detection Performance between Tissue and Liquid Biopsy NGS

Mutation Type	Example Genes	Tissue NGS Sensitivity (Range)	Liquid Biopsy NGS Sensitivity (Range)	Reported Concordance Rate
Point Mutations	EGFR, KRAS, BRAF V600E	93% (for EGFR) [28]	80% (for EGFR) [28]	EGFR: ~85% [24]KRAS: ~65% [24]
Gene Fusions	ALK, ROS1, RET	99% (for ALK) [28]	Limited sensitivity [28]	ALK: ~78% [24]ROS1: ~59% [24]
Insertions/Deletions	EGFR exon 19 del	High [28]	Moderate to High [27]	Varies by specific alteration
Copy Number Variations	MET, ERBB2	High	Lower than for SNVs/Indels [25]	Varies by tumor burden and platform

This mutation-specific performance is reflected in real-world clinical outcomes. A study on advanced NSCLC found that liquid biopsy NGS successfully identified actionable mutations in 45.59% of patients, directly enabling targeted treatment [27]. Furthermore, the stage of disease significantly impacts concordance; the same study showed a marked increase in Positive Percentage Agreement (PPA) from 28.57% in Stage III to 99.20% in Stage IV disease, underscoring that liquid biopsy sensitivity is closely tied to tumor burden [27].

Experimental Protocols for Concordance Validation

Robust validation of NGS platform performance for tissue and liquid biopsy concordance requires a structured experimental approach. The following methodology, adapted from recent studies, outlines the key steps.

Sample Collection and Processing

• Patient Cohort: Enroll patients with confirmed advanced cancer (e.g., stage III/IV NSCLC). Paired tissue and blood samples should be collected, with tissue biopsy preceding or being concurrent with blood draw (within a narrow time window, e.g., <14 days) [25] [27].
• Tissue Sample Handling: Tumor tissue is formalin-fixed and paraffin-embedded (FFPE). DNA is extracted using specialized kits (e.g., QIAmp FFPE Tissue Kit), and tumor content is quantified to ensure it meets a minimum threshold (e.g., >20%) [27].
• Liquid Sample Handling: Peripheral blood (typically 10-20 mL) is collected in cell-free DNA preservation tubes (e.g., Streck Cell-Free DNA BCT). Plasma is separated via a two-step centrifugation protocol (e.g., 1600 × g for 10 min, then 16,000 × g for 10 min) to isolate plasma from cells and debris. Cell-free DNA (cfDNA) is then extracted from 4-5 mL of plasma using a commercial kit (e.g., Nucleic Acid Extraction Kit, Beijing USCI Medical Devices Co., Ltd.) and quantified using a high-sensitivity assay (e.g., Qubit dsDNA HS assay) [27].

Next-Generation Sequencing Workflow

The core NGS workflow is similar for both sample types but requires optimization for the differing quality and quantity of input DNA.

Diagram: NGS Wet-Lab and Analysis Workflow for Tissue and Liquid Biopsy

Data Analysis and Concordance Assessment

• Bioinformatic Processing: Raw sequencing reads (FASTQ) are subjected to quality control (e.g., using Trimmomatic). Reads are aligned to a reference genome (e.g., GRCh37/hg19) using aligners like BWA-Mem. Duplicate reads are marked (e.g., with Picard), followed by variant calling using tools such as GATK or VarScan. Detected variants are then annotated using tools like ANNOVAR [29] [27].
• Critical Liquid Biopsy Parameters: For ctDNA analysis, a minimum mean sequencing depth (e.g., >1400x) and a defined variant allele frequency (VAF) cutoff (e.g., 0.2%) are established to ensure detection sensitivity and specificity, often validated against droplet digital PCR (ddPCR) [27].
• Concordance Calculation: For each mutation, a 2x2 contingency table is constructed against the tissue biopsy reference standard to calculate Positive Percentage Agreement (PPA), Negative Percentage Agreement (NPA), overall percent agreement, sensitivity, and specificity [27] [28].

Comparative Data on NGS Platforms

NGS platforms vary in their technology, throughput, and performance, which can influence the results and concordance rates in comparative studies.

Table 2: Technical Comparison of Selected NGS Platforms

Platform	Technology	Max Data Output per Run	Key Performance Metrics	Strengths / Applications
Illumina NovaSeq X	Sequencing-by-Synthesis (SBS)	Up to 16 Tb (ultra-high)	Q30: >97.37% [30]	Gold standard for high-throughput WGS, large cohort studies
Illumina NovaSeq 6000	Sequencing-by-Synthesis (SBS)	Up to 6 Tb (high)	Q30: ~94.89% [30]	High-throughput clinical and research genomics
Sikun 2000	Sequencing-by-Synthesis (SBS)	200 Gb (desktop)	Q30: ~93.36%; High depth, low duplication rate [30]	Cost-effective; suitable for focused panels, decentralized labs
Ion Torrent (Thermo Fisher)	Ion Semiconductor Sequencing	Varies by model	Faster run times; homopolymer errors [31]	Rapid turnaround for targeted sequencing

A recent independent evaluation of the Sikun 2000 desktop sequencer demonstrated its competitive performance. When compared to Illumina's NovaSeq 6000 and NovaSeq X for whole-genome sequencing, the Sikun 2000 achieved a slightly higher SNP (Single Nucleotide Polymorphism) recall and precision than both Illumina platforms (Recall: 97.24% vs. 97.02% and 96.84%, respectively). However, its performance in indel detection was slightly lower (Recall: 83.08% vs. 87.08% for NovaSeq 6000) [30]. This highlights that platform choice involves trade-offs between accuracy, throughput, and cost.

Successful execution of NGS-based concordance studies relies on a suite of validated reagents, tools, and databases.

Table 3: Essential Research Reagent Solutions and Resources

Category / Item	Specific Examples	Function / Application
cfDNA Extraction Kits	Nucleic Acid Extraction Kit (USCI), QIAamp Circulating Nucleic Acid Kit (Qiagen)	Isolate high-quality, fragment-size selected cfDNA from plasma samples.
Targeted NGS Panels	AVENIO ctDNA Expanded Kit (77 genes), USCI UgenDX Lung Cancer Kit (21 genes)	Capture and sequence predefined sets of cancer-related genes from tissue or liquid DNA.
Library Prep Kits	KAPA HyperPrep Kit, Illumina DNA Prep	Prepare sequencing libraries by fragmenting DNA, adding platform-specific adapters, and amplifying.
Bioinformatic Tools	BWA (alignment), GATK (variant calling), ANNOVAR (annotation)	Process raw sequencing data, identify genetic variants, and determine their biological significance.
Reference Databases	dbSNP, COSMIC, The Cancer Genome Atlas (TCGA)	Filter out common polymorphisms and interpret the clinical relevance of detected mutations [29].

The comparison of NGS platforms for tissue and liquid biopsy reveals a landscape defined by complementary strengths rather than outright superiority. Liquid biopsy NGS offers high specificity, a minimally invasive profile, and a unique capacity for monitoring tumor evolution and therapy resistance, making it invaluable for longitudinal studies in drug development [25] [26]. However, its sensitivity is contingent on tumor burden and mutation type, and it currently has limitations in detecting fusions and CNVs. Tissue biopsy NGS remains the comprehensive gold standard for initial genomic profiling, providing a tumor's mutational landscape with high sensitivity across all variant classes [28].

For researchers and drug development professionals, the evidence supports an integrated approach rather than an exclusive choice. Leveraging both sample types maximizes the likelihood of obtaining a complete genomic profile. The choice of NGS platform—whether high-throughput workhorses like Illumina's NovaSeq series or cost-effective desktop sequencers like the Sikun 2000—should be aligned with the study's specific goals, required sensitivity, throughput needs, and budget. Future advancements will focus on standardizing assays, improving the sensitivity of liquid biopsy for all mutation types, and prospectively validating its utility in clinical trials, thereby further solidifying the role of NGS in precision oncology.

In modern oncology, the diagnostic paradigm is shifting from a reliance on single biopsy modalities to an integrated approach that leverages the unique strengths of both tissue and liquid biopsies. Tissue biopsy remains the gold standard for initial diagnosis and tumor characterization, providing critical histopathological information. In contrast, liquid biopsy has emerged as an indispensable tool for dynamic monitoring of treatment response, detecting minimal residual disease (MRD), and capturing tumor heterogeneity in real-time. Research demonstrates that their roles are not competitive but fundamentally complementary, with concordance between the two modalities serving as a powerful predictor of patient outcomes and therapeutic efficacy.

The management of advanced cancers has been transformed by precision oncology, which relies on identifying specific genomic alterations in tumors to guide targeted therapies [4]. For years, tissue biopsy has been the cornerstone of cancer diagnosis, offering a high level of laboratory standardization and accuracy [6]. However, its invasive nature, inability to fully capture spatial and temporal tumor heterogeneity, and impracticality for repeated sampling represent significant limitations [6] [32].

Liquid biopsy, which analyzes tumor-derived components such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) from blood or other bodily fluids, provides a minimally invasive alternative [6] [26]. Its strengths lie in dynamic monitoring, with the potential for real-time tracking of tumor evolution, assessment of treatment response, and detection of resistance mechanisms [32].

The relationship between these two modalities is defined by their complementary strengths. As the phase II ROME trial highlights, investigating the concordance and discordance in molecular alterations between tissue and liquid biopsies is critical for precision oncology, as tumor characteristics in different sites can lead to the identification of different clinically actionable targets [4].

Quantitative Data: Comparing Modality Performance

Table 1: Detection Capabilities of Tissue vs. Liquid Biopsy

Parameter	Tissue Biopsy	Liquid Biopsy	Clinical Implication
Invasiveness	Invasive surgical procedure [4]	Minimally invasive (blood draw) [6]	Liquid biopsy allows for easier serial sampling [26]
Turnaround Time (TAT)	Slower (e.g., ~26.8 days longer in NSCLC study) [5]	Faster (e.g., 26.8 days faster in NSCLC study) [5]	Faster TAT with liquid biopsy can expedite treatment decisions [5]
Tumor Heterogeneity Capture	Limited to the biopsied site [4]	Captures DNA shed from all tumor sites [33]	Liquid biopsy provides a more comprehensive molecular profile [33]
Primary Application	Initial diagnosis & histology [6]	MRD detection & therapy monitoring [33] [34]	Tissue is diagnostic; liquid is for dynamic monitoring [34]
Sensitivity (for MRD)	Not applicable for post-treatment monitoring	High (can detect molecular relapse before radiological progression) [34]	Enables early intervention upon relapse [33]

Table 2: Clinical Performance Data from the ROME Trial (Phase II)

Patient Group	Tailored Therapy Median OS (Months)	Standard-of-Care Median OS (Months)	Tailored Therapy Median PFS (Months)	Standard-of-Care Median PFS (Months)
T+L Concordant Group	11.05 [4] [3]	7.70 [4] [3]	4.93 [4] [3]	2.80 [4] [3]
Tissue-Only Discordant Group	9.93 [4]	Information missing	3.06 [4]	Information missing
Liquid-Only Discordant Group	4.05 [4]	Information missing	2.07 [4]	Information missing

OS: Overall Survival; PFS: Progression-Free Survival

The data from the ROME trial demonstrates that patients with concordant actionable alterations identified in both tissue and liquid biopsies (the T+L group) derived the greatest benefit from tailored therapy, with a 26% reduction in the risk of death and a 45% reduction in the risk of progression [4]. This underscores the superior outcome when treatment is guided by a consensus of both biopsy modalities.

Experimental Protocols and Methodologies

The ROME Trial Protocol: A Model for Concordance Research

The ROME trial (phase II, multicenter) serves as a foundational model for investigating the clinical impact of tissue and liquid biopsy concordance [4] [3].

• Patient Cohort: 1,794 adult patients with advanced or metastatic solid tumors on their second or third line of treatment [4].
• Sample Collection: Each patient provided samples for both liquid biopsy (using FoundationOne Liquid CDx) and tissue biopsy (using FoundationOne CDx) [4].
• Sequencing and Analysis: Next-generation sequencing (NGS) was performed on all samples. A centralized Molecular Tumor Board (MTB) analyzed the results to identify actionable alterations and determine concordance (same alteration found in both) or discordance (alteration found in only one) [4] [3].
• Randomization: From the 400 patients with actionable alterations, 197 were in the concordant (T+L) group. Patients in each group were randomized to receive either tailored therapy based on the detected alteration or the clinician's choice of standard-of-care treatment [4].

Protocol for MRD Detection in Solid Tumors

Detecting Minimal Residual Disease requires highly sensitive techniques to identify trace amounts of ctDNA after curative-intent treatment [33].

• Sample Timing: Blood samples are collected at predefined timepoints: after surgery or radical-intent treatment (e.g., chemoradiotherapy), and during follow-up periods [34].
• ctDNA Analysis: The process typically uses a tumor-informed approach.
  • Plasma Separation: Blood samples are centrifuged to separate plasma from blood cells.
  • cfDNA Extraction: Cell-free DNA (cfDNA) is extracted from the plasma using specialized kits (e.g., magnetic bead-based methods that maximize recovery of fragmented cfDNA) [26].
  • Library Preparation & Sequencing: NGS libraries are prepared, for example, using panels like the Oncomine Pan-Cancer Cell-Free Assay (covering 52 genes) or the Cobas EGFR Mutation Test v2 for specific targets [34]. These assays can identify single-nucleotide variants (SNVs), indels, copy number variations (CNVs), and RNA fusions.
  • Bioinformatic Analysis: Sequencing data is analyzed with specialized algorithms to distinguish low-frequency tumor-derived mutations from background noise and clonal hematopoiesis [33].

Signaling Pathways and Biological Basis for Discordance

A critical insight from concordance research is that biological factors, not just technical ones, drive discordance between tissue and liquid biopsies. Tumor heterogeneity means different metastatic sites can have distinct genomic profiles. A tissue biopsy from one lesion may not reflect the genetics of another, which might be the primary source of ctDNA shed into the bloodstream [4].

The ROME trial found that the pathways with the highest rates of discordance between tissue and liquid biopsies were the PI3K/PTEN/AKT/mTOR and ERBB2 signaling pathways [4]. This suggests that alterations in these critical oncogenic drivers may be spatially heterogeneous within tumors.

Diagram 1: Biological Basis of Biopsy Discordance. Spatial tumor heterogeneity can lead to different genomic profiles being captured by a single-site tissue biopsy versus a liquid biopsy, which aggregates material from all tumor sites.

The Scientist's Toolkit: Key Research Reagents & Platforms

Table 3: Essential Research Solutions for Biopsy Concordance Studies

Research Tool	Type/Function	Example Products/Categories
NGS Platform for Tissue	Comprehensive genomic profiling of FFPE tissue samples.	FoundationOne CDx [4]
NGS Platform for Liquid Biopsy	Comprehensive genomic profiling of ctDNA from blood.	FoundationOne Liquid CDx [4]
cfDNA Extraction Kits	Maximize recovery of short, fragmented cfDNA from plasma/serum.	Magnetic bead-based kits (e.g., from BioChain) [26]
Targeted NGS Panels	Focused sequencing for MRD monitoring and specific mutations.	Oncomine Pan-Cancer Cell-Free Assay [34], Cobas EGFR Mutation Test v2 [34]
Automation Systems	High-throughput, consistent sample processing for NGS.	Compatibility with automated liquid handlers [26]

The evidence unequivocally supports a collaborative diagnostic model where tissue biopsy provides the initial foundational diagnosis, while liquid biopsy enables longitudinal monitoring of disease dynamics and MRD. The concordance between tissue and liquid biopsies is not merely a technical metric but a robust biomarker in itself, identifying patients most likely to achieve superior outcomes with tailored therapies [4] [3]. For researchers and drug developers, integrating both modalities in clinical trial design and diagnostic algorithms is paramount. This strategy promises to refine precision oncology, enhance patient selection for targeted therapies, and ultimately improve survival outcomes in advanced cancer.

The advent of precision oncology has revolutionized cancer treatment, shifting the paradigm from a one-size-fits-all approach to targeted strategies based on specific molecular alterations. Among the numerous genomic changes identified in cancer, alterations in FGFR, IDH1, ERBB2 (HER2), and KRAS represent some of the most clinically actionable targets across diverse tumor types. These alterations drive oncogenesis through distinct yet sometimes interconnected signaling pathways, including MAPK, PI3K-AKT, and metabolic reprogramming. The clinical utility of targeting these alterations, however, is profoundly influenced by technical and biological factors, particularly the concordance between tissue and liquid biopsy results. Emerging evidence suggests that discordance between biopsy modalities may reflect tumor heterogeneity and impact therapeutic outcomes, making this a critical consideration in both clinical practice and drug development [3] [4]. This guide provides a comprehensive comparison of these four major alteration types, focusing on their identification, clinical relevance, and the critical role of biopsy concordance in precision oncology.

Comparative Genomic Alteration Landscape

The prevalence and clinical actionability of FGFR, IDH1, ERBB2, and KRAS alterations vary significantly across cancer types. Understanding this landscape is fundamental for appropriate patient stratification and biomarker-driven drug development.

Table 1: Comparative Landscape of Actionable Alterations

Alteration	Common Tumor Types	Prevalence in Specific Contexts	Key Alteration Types
FGFR	Intrahepatic Cholangiocarcinoma (iCCA), Breast Cancer, Urothelial Carcinoma	10-15% of iCCA [35]; >25% of early HR+ breast cancer show FGFR1/2 amplification/overexpression [36]	Fusions/rearrangements (especially FGFR2 in iCCA), amplifications, mutations
IDH1	Acute Myeloid Leukemia (AML), Intrahepatic Cholangiocarcinoma (iCCA)	~20% of AML [37]; 10-20% of iCCA [35]	Missense mutations at specific hotspots (e.g., IDH1 R132)
ERBB2 (HER2)	Breast, Gastric, Colorectal, Biliary Cancers	~6% of RAS wild-type metastatic CRC [38]; 10-15% of extrahepatic CCA [35]	Gene amplification, protein overexpression, oncogenic mutations
KRAS	Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Cancer	11-16% of NSCLC (G12C variant) [39]; 3-4% of all CRC (G12C variant) [39]	Missense mutations, predominantly at codon 12 (e.g., G12C, G12D, G12V)

The anatomical and molecular subtype of a cancer heavily influences the prevalence of these alterations. For instance, in biliary tract cancers, FGFR2 fusions are predominantly found in intrahepatic cholangiocarcinoma (iCCA), while ERBB2 amplifications are more common in extrahepatic CCA and gallbladder carcinomas [40] [35]. Similarly, the KRAS G12C mutation has a distinct epidemiological profile, showing a strong association with smoking in NSCLC and a higher prevalence in left-sided colorectal cancers [39]. These patterns underscore the necessity for primary site-driven genomic testing to guide therapy selection.

Tissue and Liquid Biopsy Concordance

The ROME trial, a pivotal phase II multicenter study, provides critical insights into the concordance between tissue (T) and liquid (L) biopsy for detecting actionable alterations and its direct impact on patient outcomes. The trial enrolled 1,794 patients with advanced solid tumors and performed next-generation sequencing on both tissue and liquid biopsies [3] [4].

• Concordance Rates: The same actionable alteration was identified in both tissue and liquid biopsies (T+L group) in 49.2% of the 400 patients with actionable findings. Actionable alterations were found exclusively in tissue in 34.7% of cases and exclusively in liquid biopsy in 16% of cases [3] [4].
• Impact on Therapeutic Outcomes: Patients in the T+L group who received tailored therapy based on the concordant finding experienced significantly improved outcomes compared to standard of care, with a median overall survival (OS) of 11.05 vs. 7.70 months and a median progression-free survival (PFS) of 4.93 vs. 2.80 months [3]. The survival benefit from tailored therapy was less pronounced or absent in patients with discordant results (tissue-only or liquid-only) [3] [4].
• Discordance by Pathway: The ROME trial found that the pathways with the highest rates of discordance between tissue and liquid biopsies were the PI3K/PTEN/AKT/mTOR and ERBB2 pathways [4].

These findings highlight that concordance between biopsy modalities is a potential biomarker for improved outcomes with tailored therapy, likely because it reflects a more homogeneous and systemic presentation of the targetable alteration.

Therapeutic Applications and Clinical Data

Targeting FGFR, IDH1, ERBB2, and KRAS alterations has led to the approval of multiple agents and has demonstrated significant clinical efficacy, though response can be influenced by co-mutations and biopsy concordance.

Table 2: Targeted Therapies and Clinical Outcomes

Alteration	Examples of Approved/Investigational Therapies	Reported Efficacy in Specific Populations
FGFR	Pemigatinib, Infigratinib, Futibatinib, Rogaratinib	In FGFR2-fused iCCA: mPFS of ~7 months, mOS of ~17-21 months [35]. In HR+ MBC (FGFR-amplified, ESR1/PIK3CA WT): mPFS 9.1 vs 1.9 months [36].
IDH1	Ivosidenib	Approved for mutant IDH1 iCCA and AML [35].
ERBB2 (HER2)	Trastuzumab + Tucatinib, Trastuzumab-Deruxtecan, Neratinib	In ERBB2-mutant solid tumors: ORR 37%, DCR 68%, mPFS 4.4 months [41]. Efficacy linked to clonal mutations and tyrosine kinase domain location [41].
KRAS G12C	Sotorasib, Adagrasib, Divarasib	Approved for previously treated NSCLC and CRC [39].

Key Insights from Clinical Data

• Clonality and Mutation Location Matter: For ERBB2-mutant cancers, therapy is more effective when the mutation is clonal (rather than subclonal) and when located in the tyrosine kinase domain [41].
• Co-mutations Drive Resistance: The efficacy of an FGFR inhibitor-based combo in HR+ breast cancer was effective only in tumors wild-type for both ESR1 and PIK3CA activating mutations, as these co-mutations can confer resistance [36].
• Real-World Safety Profiles: A real-world analysis of FGFR inhibitors revealed important adverse events (AEs). The median time-to-onset of AEs differed among agents: 56.5 days for erdafitinib compared to 29 days for pemigatinib and 25 days for futibatinib, informing clinical monitoring schedules [42].

Experimental Protocols for Alteration Identification

Robust identification of these alterations is foundational for research and clinical application. The following methodologies are cited from key studies.

Genomic Profiling and Alteration Identification

• Tissue DNA Analysis: The Memorial Sloan Kettering (MSK) cohort studies and the Copenhagen Prospective Personalized Oncology (CoPPO) trial utilized whole-exome sequencing and targeted sequencing panels (e.g., MSK-IMPACT) on formalin-fixed paraffin-embedded (FFPE) tumor tissue or biopsies preserved in RNA-later to identify oncogenic variants, amplifications, and fusions [40] [41]. Sequencing reads were processed using GATK Mutect2 Best Practices guidelines, and somatic variants were classified as pathogenic, benign, or variants of unknown significance (VUS) using tools like Clinical Insight (QCI) Interpret Translational software, based on recommendations from ClinGen, CGC, and VICC [41].
• Liquid Biopsy Analysis: In the CoPPO trial and ROME trial, circulating tumor DNA (ctDNA) was analyzed from plasma samples. The ROME trial used FoundationOne Liquid CDx for liquid biopsy analysis [4], while the CoPPO trial used the TruSight Oncology 500 HT gene panel or custom NGS panels on cfDNA to a minimum median coverage of 600x [41]. Droplet digital PCR (ddPCR) was also employed in some studies for high-sensitivity monitoring of specific mutations, such as IDH1/2 in AML [37].

Concordance Assessment and Functional Validation

• Concordance Definition: In the ROME trial, concordance was strictly defined as the detection of the same druggable alteration in both tissue and liquid biopsies [3] [4]. All results were reviewed by a centralized Molecular Tumor Board (MTB) to identify actionable alterations and assess concordance [3].
• Functional Preclinical Models: To validate therapeutic hypotheses and understand mechanisms of resistance, the ROGABREAST trial employed a co-clinical trial design using patient-derived organoids (PDOs). These PDOs, established from patient biopsies after disease progression, were treated with the same drug combinations planned for the clinical trial (e.g., rogaratinib, fulvestrant, palbociclib) to pre-assess efficacy and link response to the PDO's genomic profile [36].

Signaling Pathways and Alteration Impact

The actionable alterations in FGFR, IDH1, ERBB2, and KRAS drive tumorigenesis by constitutively activating key pro-survival and proliferative signaling pathways. The diagram below illustrates the core signaling pathways and the points of therapeutic intervention.

This diagram illustrates how these alterations hijack normal cellular signaling:

• FGFR and ERBB2 are receptor tyrosine kinases (RTKs) that, when altered, constitutively activate downstream pathways [40].
• KRAS mutations, particularly G12C, lock the KRAS protein in an active, GTP-bound state, leading to persistent signaling through the MAPK pathway (RAF-MEK-ERK) and others [39].
• IDH1 mutations confer a neomorphic activity, leading to the production of the oncometabolite D-2-hydroxyglutarate (2HG), which competitively inhibits α-ketoglutarate-dependent enzymes, causing widespread epigenetic dysregulation and blocking cell differentiation [37] [35].

The Scientist's Toolkit: Essential Research Reagents and Platforms

Advancing research and clinical application in this field relies on a standardized set of reagents, platforms, and methodologies.

Table 3: Key Research Reagent Solutions

Tool Category	Specific Examples	Primary Function in Research
Sequencing Panels	FoundationOne CDx, FoundationOne Liquid CDx, MSK-IMPACT, TruSight Oncology 500	Comprehensive genomic profiling of tissue (CDx) and liquid (Liquid CDx) biopsies to identify actionable alterations.
Bioinformatics Tools	GATK Mutect2, Clinical Insight (QCI) Interpret	Processing and annotation of sequencing data; classification of somatic variants.
Specialized Assays	FISH, RNAScope, ddPCR	Detecting gene amplifications (FISH), mRNA overexpression (RNAScope), and high-sensitivity monitoring of specific mutations (ddPCR).
Preclinical Models	Patient-Derived Organoids (PDOs)	Ex vivo testing of drug combination efficacy and resistance mechanisms in a clinically relevant model.

The identification and targeting of FGFR, IDH1, ERBB2, and KRAS alterations represent a cornerstone of modern precision oncology. The clinical efficacy of targeting these alterations is well-established but is nuanced by factors such as anatomical cancer subtype, specific alteration type and domain, clonality, and the presence of co-alterations. Critically, emerging evidence from the ROME trial indicates that concordance between tissue and liquid biopsy is a significant factor, with patients whose actionable alteration is detected in both modalities deriving the greatest benefit from matched therapy. This underscores the potential value of a combined biopsy approach in selected clinical contexts to optimize patient selection. Future research should focus on standardizing concordance assessment, understanding the biological implications of discordance, and developing novel therapeutic strategies to overcome resistance, thereby expanding the reach and impact of targeted therapies.

The integration of liquid biopsy into clinical trial enrollment represents a paradigm shift in precision oncology, moving beyond traditional tissue-based genomic profiling. This approach leverages circulating tumor DNA (ctDNA) and other blood-based biomarkers to match patients with targeted therapies, offering a less invasive and more dynamic assessment of tumor genetics. The critical scientific premise underpinning this strategy is the concordance between tissue and liquid biopsy results, a relationship that directly influences patient outcomes in therapeutic trials. Evidence from major studies confirms that when the same druggable alteration is identified in both tissue and liquid biopsy (a concordant result), patients experience significantly improved survival outcomes when receiving matched targeted therapy [3]. This establishes concordance not merely as a technical metric but as a fundamental biomarker for treatment efficacy. The subsequent sections of this guide will objectively compare the performance of various liquid biopsy platforms and approaches, providing researchers and drug developers with the experimental data and methodologies needed to implement plasma-first patient enrollment strategies.

Clinical Evidence and Outcome Data

Robust evidence from prospective clinical trials demonstrates the viability of using liquid biopsy for patient enrollment and the critical importance of tissue-plasma concordance.

Key Trials Supporting Plasma-Based Enrollment

Table 1: Clinical Trials Utilizing Liquid Biopsy for Patient Stratification

Trial Name	Study Population	Liquid Biopsy Platform	Key Findings Related to Plasma Profiling
NCI-MATCH [43]	2,194 patients with rare cancers, plasma available	Illumina TruSight Oncology 500 ctDNA (CGP)	- 85.5% of cancer-driving mutations in tissue were also identified by ctDNA CGP.- High correlation for oncogenic mutations: 98.1% (SCLC), 96% (Esophageal), 94.6% (Cholangiocarcinoma).- Identified additional biomarkers (e.g., MSI-H, FGFR2 fusions) not detected by original tissue test.
ROME Trial [3] [14]	1,794 patients with advanced solid tumors; 400 randomized	FoundationOne Liquid CDx	- Concordance (same druggable alteration in both): 49%.- Discordance: Alterations found only in tissue (35%) or only in liquid (16%).- TT in concordant group improved mOS (11.05 vs. 7.70 months) and mPFS (4.93 vs. 2.80 months). Benefit was less pronounced in discordant groups.
NILE Study [44]	Advanced Non-Small Cell Lung Cancer (NSCLC)	Guardant360	- Demonstrated non-inferiority of plasma-first approach to tissue genotyping for detecting guideline-recommended biomarkers.- Plasma NGS provided faster results (9 vs. 15 days) and a more complete tumor genotype.
LIBELULE Trial [44]	319 patients with radiological suspicion of advanced lung cancer	InVisionFirst-Lung	- In unselected patients, early LBx did not significantly shorten time to treatment.- In advanced non-squamous NSCLC subgroup, LBx significantly reduced time to treatment start (29.5 vs. 40.3 days).

Impact of Concordance on Therapeutic Outcomes

The ROME trial offers pivotal insights into how concordance directly impacts patient survival, which is crucial for designing clinical trial endpoints.

Table 2: Impact of Biopsy Concordance on Survival Outcomes in the ROME Trial [3]

Biopsy Result Group	Median Overall Survival (OS) with Tailored Therapy	Median Progression-Free Survival (PFS) with Tailored Therapy
Concordant (T+L+)	11.05 months	4.93 months
Tissue-Only (T+L-)	9.93 months	3.06 months
Liquid-Only (T-L+)	4.05 months	2.07 months

This data underscores that the combined use of tissue and liquid biopsy maximizes the detection of actionable alterations and helps identify a patient population most likely to derive significant benefit from tailored therapies [14].

Methodologies and Analytical Approaches

The reliability of plasma profiling in clinical trials hinges on sophisticated and validated experimental protocols.

Comprehensive Genomic Profiling (CGP) via NGS

Next-generation sequencing (NGS) is the technological backbone of modern liquid biopsy, allowing for the detailed analysis of hundreds of genes from a single plasma sample [43] [45].

• Sample Collection and Processing: Blood samples are collected in specialized tubes (e.g., Streck Cell-Free DNA BCT) to preserve ctDNA. Plasma is separated via double centrifugation to avoid cellular contamination. Cell-free DNA (cfDNA) is then extracted from the plasma [26] [6].
• Library Preparation and Sequencing: Extracted cfDNA undergoes library preparation, often involving unique molecular identifiers to tag original DNA molecules and reduce sequencing errors. The Illumina TruSight Oncology 500 ctDNA assay, for example, uses hybrid capture-based technology to enrich for relevant genomic regions before sequencing on Illumina NGS platforms [43].
• Bioinformatic Analysis: Sequencing data is processed through a complex bioinformatics pipeline. This includes:
  • Alignment: Reads are aligned to a reference human genome.
  • Variant Calling: Specialized algorithms (e.g., MuTect for somatic mutations) identify single nucleotide variants, insertions/deletions, copy number alterations, and gene fusions against a background of wild-type DNA.
  • Tumor Fraction (TF) Estimation: The ctDNA fraction in the total cfDNA is calculated, which is critical for interpreting negative results and assessing assay sensitivity [44] [14].

Concordance Analysis Protocol

The protocol for determining concordance, as executed in trials like ROME, involves a direct, gene-by-gene, and alteration-by-alteration comparison.

• Centralized Testing and Review: To minimize inter-lab variability, matched tissue and liquid biopsy samples from the same patient are subjected to CGP. In the ROME trial, this was done using FoundationOne CDx for tissue and FoundationOne Liquid CDx for plasma [3].
• Actionable Alteration Matching: A centralized Molecular Tumor Board reviews the results from both biopsies. A "druggable" or "actionable" alteration is deemed concordant if the identical mutation (e.g., the same EGFR L858R mutation) is identified in both the tissue and liquid biopsy specimens.
• Discordance Resolution: Alterations found in only one biopsy type are categorized as "tissue-only" or "liquid-only." The potential reasons for discordance (e.g., low tumor fraction, tumor heterogeneity, clonal hematopoiesis) are investigated [3].

Diagram 1: Concordance analysis workflow showing the parallel processing of tissue and liquid biopsy samples for comparative genomic profiling. MTB: Molecular Tumor Board.

The Researcher's Toolkit: Essential Reagents and Materials

Successful implementation of plasma profiling in trials requires a suite of specialized research reagents and analytical tools.

Table 3: Key Research Reagent Solutions for Liquid Biopsy in Clinical Trials

Item / Solution	Function / Application	Example Context
cfDNA Preservation Blood Collection Tubes	Stabilizes nucleated blood cells to prevent genomic DNA contamination and preserve ctDNA profile post-phlebotomy.	Streck Cell-Free DNA BCT tubes are industry standard for multi-center trial sample integrity.
NGS Library Prep Kit for Liquid Biopsy	Prepares fragmented, low-input cfDNA libraries for sequencing, often incorporating UMI for error correction.	Illumina TSO 500 ctDNA v2 kit; FoundationOne Liquid CDx assay.
Hybrid Capture Probes	Biotinylated probes designed to enrich specific genomic regions (e.g., cancer-related genes) from sequencing libraries.	Pan-cancer probe sets covering 500+ genes in TSO 500.
Bioinformatic Variant Callers	Specialized software algorithms to distinguish low-frequency somatic mutations from sequencing noise and germline variants.	Tools like MuTect2, VarScan2; often integrated into commercial platform software.
Tumor Fraction Estimation Algorithms	Computes the proportion of cfDNA derived from the tumor, a critical quality metric for interpreting negative results.	IchorCNA for copy number-based estimation; epigenetic methods.

Conceptual Framework: Integrating Liquid Biopsy into Trial Enrollment

The decision to enroll a patient in a clinical trial based on liquid biopsy results is a multi-factorial process that weighs molecular findings, technical assay performance, and clinical context.

Diagram 2: Clinical decision pathway for trial enrollment based on liquid biopsy results, highlighting the role of tumor fraction and combined profiling.

The body of evidence confirms that enrolling patients in clinical trials based on plasma profiling is a clinically valid and increasingly essential strategy. The high agreement between tissue and liquid CGP, as demonstrated in the NCI-MATCH trial, provides confidence that liquid biopsy can effectively identify patients for targeted therapy arms [43]. The critical insight from the ROME trial is that concordance itself is a predictive biomarker; patients with alterations detected in both mediums derive the greatest survival benefit from tailored therapy [3]. Therefore, the optimal strategy for drug developers is not to replace tissue with liquid, but to integrate both modalities to maximize the detection of actionable alterations and identify the patient population most likely to respond. Future directions will focus on standardizing assays, validating the use of tumor fraction to guide clinical decisions, and expanding the use of liquid biopsy into earlier-stage disease trials for minimal residual disease monitoring [44] [14].

Addressing Discordance and Optimizing Diagnostic Yield

The integration of tissue and liquid biopsies represents a transformative advancement in precision oncology, enabling comprehensive tumor profiling that accounts for spatial and temporal heterogeneity. However, the diagnostic pathway—from sample collection to analysis—is fraught with numerous pre-analytical and technical challenges that can compromise result accuracy and clinical utility. Understanding these sources of error is paramount for researchers and drug development professionals seeking to optimize biopsy concordance and reliable biomarker detection. This analysis systematically examines the factors contributing to technical failures across both biopsy modalities, providing evidence-based insights into error mitigation strategies essential for robust research and clinical application.

Pre-analytical Variables: A Primary Source of Error

Pre-analytical variables encompass all factors affecting sample integrity before laboratory analysis. These variables constitute the most prevalent source of error in molecular diagnostics, significantly impacting downstream results.

Tissue Biopsy Pre-analytical Challenges

Traditional tissue biopsies remain the gold standard for tumor characterization but are particularly vulnerable to pre-analytical errors that can alter molecular profiles.

Table 1: Common Pre-analytical Errors in Tissue Biopsies

Error Category	Specific Examples	Impact on Molecular Analysis
Sample Acquisition	Insufficient tissue [46], improper biopsy type [46], low tumor cellularity [46]	Failed sequencing assays; inaccurate variant calling
Sample Processing	Delay in fixation [47], improper fixative type/volume [48] [47], inadequate container [48]	Protein degradation/alteration [47]; nucleic acid degradation
Documentation Errors	Incomplete request forms [48], mislabeled specimens [49], missing clinical data [48]	Incorrect interpretation; delayed diagnosis
Transport & Storage	Temperature excursions, prolonged storage [46], excessive transport time	Degradation of biomolecules

A comprehensive study of 1,528 tumor specimens submitted for next-generation sequencing (NGS) testing revealed a 22.5% failure rate, with pre-analytical causes accounting for approximately 90% of these failures [46]. Insufficient tissue was the dominant cause (65% of failures), followed by insufficient DNA yield (28.9%) [46]. Multivariate analysis identified clinical setting (initial diagnosis vs. recurrence), biopsy type, and site as significant predictors of failure [46].

Beyond sample adequacy, tissue stability presents a critical challenge. Excised tissue remains biologically active, undergoing rapid metabolic changes that can profoundly alter biomarker levels. Protein phosphorylation states, crucial for signaling pathway analysis, are particularly labile. One study demonstrated that phosphoprotein biomarkers can be elevated or suppressed in a time-dependent manner post-excision, failing to represent in vivo states [47]. This instability necessitates strict standardization of procurement protocols for reliable protein biomarker analysis.

Liquid Biopsy Pre-analytical Variables

Liquid biopsies, while minimally invasive, introduce distinct pre-analytical considerations that affect analytical sensitivity and specificity.

Table 2: Key Pre-analytical Variables in Liquid Biopsy

Variable	Challenge	Consequence
Blood Collection	Tube type, sample volume, hemolysis	cfDNA yield; false variants
Time to Processing	Delay in plasma separation	Increased background wild-type DNA; false negatives
Plasma vs. Serum	Choice of matrix	Differences in cfDNA recovery from leukocyte lysis
Sample Storage	Temperature, freeze-thaw cycles	Degradation of cfDNA/ctDNA

A significant biological confounder in liquid biopsy is clonal hematopoiesis of indeterminate potential (CHIP), where white blood cells acquire mutations that are detectable in cell-free DNA (cfDNA). These mutations can be misinterpreted as tumor-derived, leading to false positives. One study found that mutations in genes like JAK2, TP53, and KRAS detected in plasma often originated from white blood cells rather than the tumor [50]. This underscores the necessity of sequencing matched peripheral blood cells to distinguish true circulating tumor DNA (ctDNA) from CHIP-derived variants.

Technical Failures and Analytical Limitations

Technical failures occur during the analytical phase and are intrinsically linked to the methodologies and technologies employed.

Technical Failures in Tissue Molecular Analysis

In the NGS study previously cited, 6.1% of failures occurred during library preparation [46]. These failures were independently associated with DNA degradation and the type of biopsy procedure [46]. Factors such as DNA purity and degradation significantly impact the success of complex molecular assays, highlighting the interplay between pre-analytical conditions and analytical performance.

Analytical Challenges in Liquid Biopsy

The fundamental challenge in liquid biopsy is the ultrarare detection of tumor-derived DNA fragments against a high background of wild-type DNA. Key limitations include:

• Limited Sensitivity in Low-Shedding Tumors: Some tumors do not release sufficient ctDNA into the bloodstream, leading to false-negative results [50] [51].
• Detection Limit Constraints: Even with advanced technologies, detecting mutations below a certain variant allele frequency remains challenging [14] [51].
• Molecular Artifacts: DNA damage during sample processing or sequencing can introduce errors that mimic true mutations [51].

Emerging technologies are addressing these challenges. For instance, the MUTE-Seq method leverages a highly precise FnCas9 variant to selectively eliminate wild-type DNA, enabling highly sensitive detection of low-frequency mutations in ctDNA [14]. Molecular barcoding, which involves tagging individual DNA molecules before amplification, reduces technical errors by generating consensus sequences, thereby improving detection limits [51].

Impact on Biopsy Concordance and Clinical Implications

Discordance between tissue and liquid biopsy results can stem from both biological (tumor heterogeneity) and technical factors. Understanding the source is critical for interpretation.

The phase 2 ROME trial provides compelling evidence on the value of combined profiling. The study found that combining tissue and liquid biopsies identified more patients with actionable alterations than either method alone. However, concordance was imperfect. Actionable alterations were detected in both biopsy types in only 49.2% of patients, while 34.7% were tissue-only and 16% were liquid-only [52]. This discordance was attributed to factors including technical test failures (21%) and differences in the detection of specific molecular alterations [52].

Crucially, patient outcomes were superior when therapies were matched to alterations identified concordantly by both methods. Patients with concordant findings who received tailored therapy achieved a median overall survival of 11.05 months versus 7.7 months with standard care [14] [52]. This underscores that concordance may reflect a more ubiquitous targetable alteration across metastatic sites, and that technical failures contributing to discordance can directly impact therapeutic efficacy.

Methodological Approaches for Error Mitigation

Experimental Protocols for Enhanced Detection

Protocol: MUTE-Seq for Ultrasensitive MRD Detection The MUTE-Seq method was designed for minimal residual disease (MRD) monitoring where ctDNA fractions are exceptionally low [14].

• Input Material: Cell-free DNA extracted from patient plasma.
• CRISPR-Cas9 Enrichment: An engineered, high-fidelity FnCas9 protein (FnCas9-AF2) is used to create specific double-strand breaks in wild-type DNA sequences.
• Selective Digestion: The perfectly matched wild-type DNA is preferentially cleaved and degraded.
• Library Preparation & Sequencing: The enriched mutant DNA fragments are processed into a sequencing library. Molecular barcoding is applied to track original molecules and correct for PCR/sequencing errors.
• Data Analysis: Bioinformatic pipelines identify mutant alleles with significantly improved signal-to-noise ratio due to the reduction of wild-type background.

Protocol: Paired White Blood Cell Sequencing for CHIP Exclusion To address clonal hematopoiesis, this protocol should accompany liquid biopsy analysis [50].

• Parallel Collection: From a single blood draw, collect plasma into cfDNA tubes and a separate tube for peripheral blood cells (PBCs).
• DNA Extraction: Isolate cfDNA from plasma and genomic DNA from the PBC pellet.
• Parallel Sequencing: Sequence both the cfDNA and matched PBC gDNA using the same NGS panel.
• Variant Filtering: Any variant detected in the cfDNA that is also present in the matched PBCs is flagged as potentially originating from clonal hematopoiesis and not the tumor.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagents for Mitigating Pre-analytical and Analytical Errors

Research Reagent	Primary Function	Application Context
Streck Cell-Free DNA BCT Tubes	Stabilizes nucleated blood cells, prevents lysis and release of genomic DNA.	Liquid biopsy blood collection; reduces background wild-type DNA.
Molecular Barcodes (UID/UMI)	Uniquely tags individual DNA molecules pre-amplification.	NGS-based liquid biopsy; enables error correction via consensus sequencing.
Engineered FnCas9 (FnCas9-AF2)	Highly specific cleavage of wild-type DNA sequences.	MUTE-Seq enrichment for ultra-rare variant detection in MRD [14].
Multi-purpose Fixative Solutions	Simultaneously stabilizes proteins, nucleic acids, and tissue architecture.	Tissue biopsy preservation; maintains phosphoprotein epitopes for signaling analysis [47].
Surrogate Stability Markers	Panels of natural proteins indicating sample degradation.	Tissue quality control; assesses pre-analytical variability for biomarker studies [47].

Pre-analytical variables and technical failures represent significant, yet often preventable, obstacles in the reliable integration of tissue and liquid biopsies for cancer research and drug development. The evidence demonstrates that a substantial majority of molecular testing failures originate in the pre-analytical phase, driven by factors such as insufficient sample quality, improper handling, and biological confounders like clonal hematopoiesis. For researchers, a meticulous approach to standardizing sample procurement, processing, and analysis is non-negotiable. Employing advanced methodologies like molecular barcoding, paired white blood cell sequencing, and CRISPR-based enrichment, as part of a rigorously controlled workflow, is critical for mitigating errors, enhancing biopsy concordance, and ultimately ensuring the generation of robust, reproducible data that can reliably inform therapeutic development and clinical decision-making.

The accurate detection of genomic alterations is the cornerstone of precision oncology. However, the emerging evidence reveals significant discrepancies between two primary diagnostic modalities—tissue and liquid biopsies—particularly within the PI3K/PTEN/AKT/mTOR and ERBB2 signaling pathways. These pathways are critical regulators of cellular proliferation, survival, and metabolism, and their aberrant signaling is oncogenic across numerous cancer types [53] [54]. The phase II ROME trial, a landmark study presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, provides the first large-scale evidence that discordance between biopsy modalities directly impacts patient survival [21] [52] [55]. This guide objectively compares the performance of tissue and liquid biopsies in detecting alterations in these pathways, synthesizing recent experimental data to inform research and drug development.

Quantitative Comparison of Biopsy Discordance

The ROME trial enrolled 1,794 patients with advanced solid tumors and performed centralized next-generation sequencing on both tissue (FoundationOne CDx) and liquid biopsies (FoundationOne Liquid CDx) [21] [52]. A molecular tumor board identified 400 patients with actionable alterations. The trial's exploratory analysis quantified discordance, revealing that these two pathways are among the most challenging to assess consistently.

Table 1: Overall Discordance Rates Between Biopsy Modalities

Category	Finding	Percentage of Patients
Overall Concordance	Same actionable alteration detected in both biopsies	49.2%
Tissue-Only Detection	Actionable alteration found only in tissue biopsy	34.7%
Liquid-Only Detection	Actionable alteration found only in liquid biopsy	16.0%

Table 2: Discordance in Key Oncogenic Pathways

Pathway	Discordance Attribution	Key Reasons and Implications
PI3K/PTEN/AKT/mTOR	High discordance rate [55]	Differences in detection of molecular alterations (e.g., PIK3CA mutations, PTEN loss) [52] [54]
ERBB2 (HER2)	High discordance rate [55]	Driven by mechanisms beyond gene amplification (e.g., NRG1 ligand expression, d16ERBB2 splice variant) poorly captured by one modality [56]

Clinical Impact of Discordance on Patient Survival

The ROME trial demonstrated that the concordance between biopsies is not merely a technical issue but a critical factor influencing therapeutic success. Patients receiving tailored therapy based on alterations concordantly detected in both biopsies experienced significantly improved outcomes [21] [52].

Table 3: Survival Outcomes Based on Biopsy Concordance and Treatment Type

Patient Group	Treatment	Median Overall Survival	Median Progression-Free Survival
Concordant (Tissue+Liquid)	Tailored Therapy	11.05 months	4.93 months
Concordant (Tissue+Liquid)	Standard of Care	7.7 months	2.8 months
Tissue-Only Detection	Tailored Therapy	9.93 months	3.06 months
Liquid-Only Detection	Tailored Therapy	4.05 months	2.07 months

The data indicates that the survival benefit of tailored therapy was most pronounced in the concordant group. The notably lower survival in the liquid-only group may reflect limitations of liquid biopsies in tumor DNA shedding or the biological context of those specific alterations [52] [55].

Experimental Protocols and Mechanistic Insights

Understanding the discordance requires a deep dive into the experimental methods used to interrogate these pathways and the unique biology that complicates their detection.

Key Methodologies from cited research

1. ROME Trial Protocol (NCT04591431)

• Patient Cohort: 1,794 patients with advanced solid tumors on their second- or third-line treatment [52].
• Sequencing: Centralized next-generation sequencing using FoundationOne CDx (tissue) and FoundationOne Liquid CDx (blood) [21] [55].
• Analysis: A centralized molecular tumor board reviewed results for actionable alterations. Concordance was strictly defined as the detection of the same genomic alteration in both biopsies [21].

2. Interrogating ERBB2 Activation in Prostate Cancer

• Techniques: Immunohistochemistry (IHC) with a phospho-specific ErbB2 (Tyr1221/1222) antibody, reverse-phase protein array, and RNA sequencing in cell lines, xenografts, and clinical tumors [56].
• Models: Use of patient-derived xenograft (PDX) models like BIDPC1 and LuCaP series, passaged in male ICR-SCID mice. Castration-resistant models were developed by harvesting tumors after they regrew post-castration [56].
• Drug Testing: In vivo sensitivity testing with ErbB2 inhibitors like neratinib (40 mg/kg/day via daily oral gavage) in mouse xenograft models [56].

Biological Mechanisms Driving Discordance

The high discordance in the ERBB2 pathway is partly explained by activation mechanisms that are not reliant on gene amplification. A 2025 study found that in prostate cancer, ErbB2 signaling is rapidly activated after androgen signaling inhibition through:

• Increased Ligand Expression: Tumor cell expression of the ErbB3/ErbB2-activating ligand NRG1 was found by IHC in approximately 75% of treated tumors [56].
• Splice Variants: Increased expression of an active d16ERBB2 splice variant post-therapy [56]. These regulatory changes may be temporally and spatially heterogeneous, making them difficult to capture with a single biopsy type.

The PI3K/PTEN/AKT/mTOR pathway is a complex, frequently mutated signaling network regulating cell growth and survival [53] [54]. Discordance can arise from technical and biological factors, including differences in the detection of activating PIK3CA mutations or loss-of-function alterations in PTEN across biopsy samples [52] [54].

Visualizing Pathway Architecture and Experimental Workflow

The following diagrams illustrate the core signaling pathways and a generalized experimental workflow for concordance research, providing a visual reference for their complexity.

ERBB2 and PI3K/AKT/mTOR Pathway Crosstalk

This diagram shows the simplified ERBB2 and PI3K/AKT/mTOR pathway architecture. ERBB2 heterodimerization initiates signaling. The PI3K complex generates PIP3, which activates AKT and mTOR, driving oncogenic outputs. PTEN acts as a key negative regulator. This complex bow-tie structure with feedback loops contributes to pathway resilience and discordance.

Biopsy Concordance Research Workflow

This workflow outlines the key steps in a biopsy concordance study like the ROME trial, highlighting parallel processing of tissue and liquid samples, centralized analysis, and correlation with clinical outcomes.

The Scientist's Toolkit: Essential Research Reagents and Materials

This table catalogs key reagents and materials critical for designing experiments in this field.

Table 4: Key Reagent Solutions for Biopsy and Pathway Analysis

Research Reagent / Material	Primary Function	Example Use in Context
FoundationOne CDx	Comprehensive genomic profiling from FFPE tissue	Gold-standard tissue NGS in the ROME trial [21] [52]
FoundationOne Liquid CDx	Comprehensive genomic profiling from circulating tumor DNA (ctDNA)	Liquid biopsy NGS counterpart in the ROME trial [21] [52]
Phospho-HER2/ErbB2 (Tyr1221/1222) Antibody	Detects activated ErbB2 via IHC	Identifying ErbB2 activation in tumor samples independent of overexpression [56]
NRG1 (Heregulin) Antibody	Detects NRG1 ligand expression via IHC	Assessing ligand-driven ERBB2 activation mechanism [56]
Patient-Derived Xenograft (PDX) Models	In vivo models that recapitulate human tumor biology	Testing therapeutic responses and resistance mechanisms [56]
Neratinib	Covalent ErbB2 inhibitor	In vivo testing of ErbB2 pathway suppression in xenograft models [56]

The paradigm for genomic profiling in oncology has significantly evolved with the integration of liquid biopsies into clinical practice, presenting a less invasive alternative to tissue biopsies that can capture tumor heterogeneity. However, the utility of these circulating tumor DNA (ctDNA) assays has been historically constrained by their variable performance, particularly in sensitivity and positive predictive value at variant allele frequencies (VAFs) below 0.5% [57]. This limitation is clinically significant given that a substantial fraction of pathogenic variants occur at low VAFs; over 25% of somatic mutations in non-small cell lung cancer (NSCLC) are detected below 0.2% VAF, and across various cancers, 10-24% of hotspots in key genes like EGFR, KRAS, PIK3CA, and BRAF are found below 5% VAF [57] [58]. The critical need for enhanced sensitivity is further emphasized by evidence that variants detected at low VAF respond similarly to targeted therapies as those with higher signals, making accurate low-VAF detection imperative for personalized care delivery [57] [58].

The clinical relevance of this challenge is powerfully illustrated by the recent ROME trial, which investigated the impact of concordance between tissue and liquid biopsy on patient outcomes. This phase II study found that when the same druggable alteration was detected in both biopsy types (T+L group), patients receiving tailored therapy experienced significantly improved survival outcomes (median OS: 11.05 vs. 7.70 months; HR 0.74) compared to standard of care [3] [4]. In contrast, the survival benefit was less pronounced or absent when alterations were detected in only one biopsy type, with the liquid-only group showing the poorest outcomes (median OS: 4.05 months) [3] [4]. These findings underscore that enhancing the sensitivity of liquid biopsies to improve concordance rates is not merely a technical concern but a crucial factor in optimizing patient selection for targeted therapies and improving clinical results.

Head-to-Head Performance Comparison of Advanced Liquid Biopsy Assays

Northstar Select: A Technological Leap in Low-VAF Detection

The Northstar Select assay employs proprietary Quantitative Counting Template (QCT) technology with novel bioinformatic pipelines to minimize errors and enhance variant detection, particularly for low-abundance ctDNA [57]. This 84-gene, plasma-based, tumor-naive comprehensive genomic profiling (CGP) assay detects SNVs/Indels, CNVs, fusions, and microsatellite instability (MSI-H) with significantly improved sensitivity across all variant classes compared to existing commercial alternatives [57].

Table 1: Analytical Performance of Northstar Select vs. On-Market CGP Assays

Performance Metric	Northstar Select	Typical On-Market CGP Assays	Improvement with Northstar Select
SNV/Indel LOD₉₅ (VAF)	0.15%	>0.2%-0.5% [57]	>25% more sensitive
CNV LOD₉₅ (Copies)	2.11 (amplification)1.80 (loss)	Variable, with dramatically reduced sensitivity (28-35%) at low tumor fraction [57]	Addresses key challenge in liquid biopsy
Fusion LOD₉₅	0.30% Tumor Fraction	Not specified in search results	Enhanced detection capability
MSI-H LOD₉₅	0.07% Tumor Fraction	Not specified in search results	Enhanced detection capability
Pathogenic SNV/Indel Detection	Benchmark	Benchmark - 51%	51% more variants detected
Pathogenic CNV Detection	Benchmark	Benchmark - 109%	109% more variants detected
Null Reports (No Pathogenic Findings)	11%	20%	45% reduction

In a prospective, head-to-head comparison study of 182 patients with advanced solid tumors, Northstar Select was evaluated against on-market NGS-based ctDNA assays from CLIA/CAP laboratories with extensive validation and/or FDA approvals [57]. The assay demonstrated a 95% limit of detection (LOD) of 0.15% VAF for SNV/Indels, which was orthogonally confirmed via digital droplet PCR, representing a significant advancement over existing technologies [57]. This enhanced sensitivity resulted in nearly half the rate of null reports (11% vs. 20% in comparators) despite Northstar Select having a smaller gene panel than some competitors [57]. Critically, 91% of the additional clinically actionable SNV/indels identified by Northstar Select were detected below 0.5% VAF, precisely where conventional assays struggle most [57].

Emerging In-House Assays and Performance Benchmarks

Several other assays have also demonstrated advancements in low-VAF detection, though with varying sensitivity thresholds and methodological approaches.

Table 2: Performance Comparison of Emerging Liquid Biopsy Assays

Assay Name	Gene Coverage	Key Technological Features	Sensitivity for SNVs/Indels	Specificity for SNVs/Indels	Turnaround Time
Northstar Select [57]	84 genes	Proprietary QCT technology, optimized bioinformatic pipelines	95% LOD at 0.15% VAF	>99.9999%	Not specified
Hedera Profiling 2 (HP2) [59]	32 genes	Hybrid capture-based NGS, single DNA-only workflow	96.92% at 0.5% VAF	99.67%	Not specified
TTSH-Oncopanel [60]	61 genes	Hybridization-capture based target enrichment, machine learning variant analysis	98.23% for unique variantsMinimum detected VAF: 2.9%	99.99%	4 days

The Hedera Profiling 2 (HP2) test panel, a 32-gene hybrid capture-based NGS assay, demonstrated 96.92% sensitivity and 99.67% specificity for SNVs/Indels at 0.5% allele frequency in reference standards, with 100% sensitivity for fusion detection [59]. Meanwhile, the TTSH-Oncopanel, a 61-gene pan-cancer panel, achieved 98.23% sensitivity for detecting unique variants but with a higher minimum detectable VAF of 2.9% [60]. This assay significantly reduced turnaround time to just 4 days compared to the approximately 3 weeks typically required when outsourcing NGS testing [60].

Experimental Protocols for Validation of Low-VAF Detection

Analytical Validation of Limit of Detection

The analytical validation of Northstar Select followed a rigorous two-stage approach to establish the limit of detection (LOD) for each variant class [57]:

• Range-Finding Experiment: The assay was first evaluated on contrived materials covering a wide VAF range (0.06%-0.35%). Sensitivity was calculated for each VAF bin, determining that 95% or more variants were detected for SNVs in the 0.13-0.16% VAF range.

• LOD Confirmation: The 95% LOD was subsequently confirmed using additional samples focused on the identified VAF ranges. For CNVs and MSI, expected sensitivity limits were established through both physically and computationally contrived samples.

This validation protocol demonstrated high sensitivity and specificity across all alteration types, with the 95% LOD determined as 0.15% VAF for SNV/Indels, 2.11 copies for amplifications, 1.80 copies for losses, 0.30% tumor fraction for fusions, and 0.07% tumor fraction for MSI-H [57].

Clinical Validation Through Head-to-Head Comparison

The clinical performance of Northstar Select was assessed through a prospective, head-to-head comparative study designed to evaluate real-world impact [57]:

• Patient Recruitment: Over 200 patients with advanced solid tumors were recruited from 6 community oncology clinics and one large hospital across the United States.

• Sample Collection: At the time of sampling for the clinician's choice of comparator assay, blood was drawn simultaneously from the same venipuncture for comparison with Northstar Select.

• Comparator Assays: The study utilized NGS-based ctDNA assays from four CLIA/CAP laboratories with extensive analytical and clinical validation and/or FDA approvals as comparators.

• Analysis: The final analysis included 182 patients across more than 17 tumor types, evaluating detection rates for pathogenic variants and clinically actionable alterations across different VAF ranges.

This methodology enabled direct evaluation of the assay's technological advancements on improving identification of therapeutic options for patients with diverse solid tumors [57].

Bioinformatic Considerations for Low-Frequency Variants

The accurate detection of low-frequency variants requires specialized bioinformatic approaches beyond standard NGS analysis tools. A comparative performance assessment of four variant callers—SAMtools, Genome Analysis Toolkit (GATK), VarScan2, and SPLINTER—revealed substantial differences in sensitivity for low-VAF variants [61]:

• SAMtools demonstrated the lowest sensitivity, detecting only 49% of variants with VAFs of approximately 25%.
• GATK, VarScan2, and SPLINTER showed significantly improved performance, detecting at least 94% of variants with VAFs of approximately 10%.
• For very low-frequency variants (1-8% VAF), VarScan2 and SPLINTER achieved sensitivities of 97% and 89%, respectively, with >98% sensitivity and >99% positive predictive value in coding regions.
• Coverage analysis established that >500× coverage was required for optimal performance, with specificity of SPLINTER improving with higher coverage, while VarScan2 yielded more false positives at high coverage levels unless low-quality reads were removed prior to variant identification [61].

Figure 1: Experimental workflow for head-to-head clinical validation study, demonstrating Northstar Select's enhanced low-VAF detection capability and its impact on clinical reporting.

The Scientist's Toolkit: Essential Research Reagents and Solutions

Table 3: Key Research Reagent Solutions for Advanced Liquid Biopsy Assays

Reagent Category	Specific Product/Technology	Function in Low-VAF Detection
Proprietary Counting Technology	Quantitative Counting Template (QCT) [57]	Enables precise molecular counting and error reduction throughout sample processing
Reference Standards	Digital PCR-Validated Contrived Samples [57]	Orthogonal confirmation of VAF measurements and assay calibration
Bioinformatic Pipelines	Custom Noise-Reduction Algorithms [57]	Specifically tuned to distinguish low-VAF somatic variants from sequencing artifacts
Variant Callers	VarScan2, SPLINTER [61]	Specialized algorithms optimized for detecting low-frequency variants in NGS data
Target Enrichment System	Hybridization-Capture Based Method [60]	Efficient target capture with high uniformity for consistent coverage across genomic regions
Validation Controls	HD701 Multiplex Reference Standard [60]	Quality control for assay performance across multiple variant types and VAF ranges

The advancements in liquid biopsy sensitivity represented by assays like Northstar Select have profound implications for both clinical practice and research. The demonstrated ability to reliably detect variants below 0.5% VAF, particularly for challenging alteration classes like CNVs, addresses a critical limitation in current liquid biopsy technologies [57]. When contextualized within the ROME trial findings—where concordance between tissue and liquid biopsies predicted significantly improved outcomes with tailored therapy—the importance of these technological advances becomes clear [3] [4]. Enhanced sensitivity directly contributes to improved concordance rates, potentially expanding the population of patients who can benefit from biomarker-directed therapies.

Future directions in this field should focus on further refining detection limits while maintaining specificity, particularly for variants with VAFs below 0.1%. Additionally, standardization of validation methodologies across platforms will be essential for comparing performance between assays and establishing uniform clinical quality standards. As liquid biopsy continues to evolve toward earlier disease detection and minimal residual disease monitoring, the pursuit of enhanced sensitivity will remain a central focus in precision oncology research, ultimately enabling more patients to receive timely, targeted therapies based on comprehensive genomic profiling.

In the evolving landscape of precision oncology, the debate between tissue and liquid biopsy has often centered on which single modality is superior for genomic profiling. However, a paradigm shift is underway, moving from an "either/or" approach to an integrated "and" strategy. Groundbreaking research, particularly from the phase II ROME trial, demonstrates that the combination of both techniques is crucial for capturing a complete molecular portrait of a tumor, directly impacting patient survival [3] [52] [4]. This guide provides a comparative analysis of tissue and liquid biopsy methodologies, framed within the critical context of biomarker concordance, to inform research and drug development strategies.

Comparative Performance: Tissue vs. Liquid Biopsy

The table below summarizes the core characteristics, advantages, and limitations of each biopsy modality, illustrating their complementary nature.

Feature	Tissue Biopsy	Liquid Biopsy
Invasiveness	Invasive surgical procedure [4]	Minimally invasive (blood draw) [26] [6]
Sample Type	Direct tumor tissue [4]	Blood, urine, CSF (sources of ctDNA, CTCs, EVs) [26] [6]
Tumor Heterogeneity	Limited; samples a single anatomic site [52] [4]	Broad; captures DNA shed from multiple tumor sites [52] [4]
Sensitivity	High; considered the gold standard [62]	Can be limited, especially in low-shedding tumors [52] [62]
Primary Strength	Direct sampling, high accuracy, provides histology [6] [62]	Captures spatial heterogeneity, allows for serial monitoring [26] [52]
Key Limitation	Inability to repeatedly sample, risk of sampling bias [26] [6]	Potential for false negatives due to low ctDNA shed [52] [62]

The Concordance Paradigm: Evidence from the ROME Trial

The ROME trial (NCT04591431) provides the most compelling evidence for a combined biopsy approach. This phase II multicenter study enrolled 1,794 patients with advanced solid tumors to investigate how concordance between tissue and liquid biopsies influences outcomes from tailored therapy [3] [4].

Experimental Protocol

• Cohort: 400 patients with actionable alterations were randomized from the larger cohort.
• Sequencing Technology: Centralized next-generation sequencing (NGS) was performed using FoundationOne CDx for tissue and FoundationOne Liquid CDx for liquid biopsies [3] [52] [4].
• Analysis: A centralized Molecular Tumor Board (MTB) reviewed results. Concordance was defined as detecting the same druggable alteration in both biopsies; discordance indicated detection in only one [3].

Key Quantitative Findings on Concordance and Survival

The trial revealed that nearly half of the cases showed discordant results, underscoring the limitation of single-modality testing. More importantly, concordance was a key predictor of therapeutic success.

Table 1: ROME Trial Concordance Distribution and Survival Outcomes

Biopsy Concordance Group	Prevalence	Median Overall Survival (Months)	Median Progression-Free Survival (Months)
Concordant (T+L)	49.2% (197/400) [4]	11.05 [3] [4]	4.93 [3] [4]
Tissue-Only	34.7% (139/400) [4]	9.93 [3]	3.06 [3]
Liquid-Only	16.0% (64/400) [4]	4.05 [3]	2.07 [3]

Patients in the concordant group who received tailored therapy had significantly better outcomes than those on standard of care, with a 26% reduction in risk of death and a 45% reduction in risk of progression [4]. The survival benefit was less pronounced or absent in the discordant groups [3] [63].

Analyzing Discordance: Causes and Affected Pathways

Understanding the sources of discordance is critical for refining testing methodologies. The ROME trial analysis found that discordance was not random but concentrated in specific biological and technical areas.

Table 2: Primary Causes of Tissue-Liquid Biopsy Discordance in the ROME Trial

Cause of Discordance	Contribution	Brief Description
Molecular Alteration Detection	43.3% [63]	Differences in identifying specific gene mutations, amplifications, or fusions.
Tumor Mutational Burden (TMB)	35% [63]	Discrepancies in assessing the total number of mutations, a biomarker for immunotherapy.
Test Failures	21% [63]	Technical failures in either the tissue or liquid NGS assay.
Microsatellite Instability (MSI)	1% [63]	Differences in detecting MSI status, another key immunotherapy biomarker.

The pathways with the highest rates of discordance were PI3K/PTEN/AKT/mTOR and ERBB2 (HER2) [52] [63], suggesting that these complex genomic regions require particular attention in assay development and clinical interpretation.

The Scientist's Toolkit: Essential Reagents and Workflows

Implementing a robust combined profiling strategy requires specific tools and a clear workflow. The following diagram and table outline the key components based on the featured research.

Diagram 1: Workflow for Combined Tissue-Liquid Biopsy Profiling. This illustrates the integrated pathway from sample collection to therapy decision, as implemented in the ROME trial.

Table 3: Key Research Reagent Solutions for Integrated Profiling

Item	Function in Protocol	Example from Featured Research
FoundationOne CDx	Comprehensive genomic profiling assay for solid tumor tissue samples. Identifies substitutions, insertions/deletions, copy number alterations, and TMB, among other biomarkers [3] [4].	Used as the tissue NGS standard in the ROME trial [52] [4].
FoundationOne Liquid CDx	Comprehensive genomic profiling assay for cell-free DNA (cfDNA) from blood. Analyzes 300+ genes for the same biomarkers as the tissue assay, enabling direct comparison [3] [4].	Used as the liquid NGS standard in the ROME trial [52] [4].
Molecular Tumor Board (MTB)	A multidisciplinary team (oncologists, pathologists, bioinformaticians) that interprets complex genomic data to recommend personalized treatment strategies [3] [4].	Centralized MTB was critical for interpreting concordant and discordant results in the ROME trial [3].
Next-Generation Sequencing (NGS)	A high-throughput technology platform that allows for the parallel sequencing of millions of DNA fragments, enabling comprehensive genomic profiling from a small sample input [3] [6].	The foundational technology for both FoundationOne CDx and Liquid CDx assays.

Critical Pathways and Future Directions

The consistent finding of high discordance in the PI3K/PTEN/AKT/mTOR and ERBB2 pathways highlights specific areas where combined biopsy is essential. The following diagram maps the PI3K pathway, a frequent source of discordance.

Diagram 2: Simplified PI3K/PTEN/AKT/mTOR Signaling Pathway. This pathway was identified in the ROME trial as having one of the highest rates of tissue-liquid biopsy discordance [52] [63]. Alterations in genes like PIK3CA and PTEN are key therapeutic targets.

Future research directions will focus on validating these findings in larger cohorts, integrating serial liquid biopsy sampling to monitor clonal evolution dynamically, and developing more sensitive assays to reduce technical discordance, particularly in critical pathways like PI3K and ERBB2 [4] [63].

The evidence unequivocally supports a synergistic approach to cancer profiling. While tissue biopsy remains the foundational gold standard, liquid biopsy provides an indispensable, complementary lens on tumor heterogeneity and evolution. For researchers and drug developers, the key takeaway is that concordance between tissue and liquid biopsies is not merely a technical metric; it is a robust biomarker predictive of therapeutic efficacy. Integrating both modalities from the outset of study design and clinical development plans is no longer optional but essential for advancing precision oncology and delivering improved outcomes for patients.

Clinical Validation, Comparative Performance, and Impact on Outcomes

In precision oncology, the reliable detection of genomic alterations directly influences patient eligibility for targeted therapies. The concordance between tissue and liquid biopsy results has emerged as a critical factor for predicting treatment success. Recent research from the phase II ROME trial demonstrates that patients with concordant findings between tissue and liquid biopsies—where the same druggable alteration was identified in both sample types—experienced significantly improved survival outcomes when receiving tailored therapy compared to standard of care (median overall survival of 11.05 vs. 7.70 months) [3] [4]. This finding underscores that analytical sensitivity, particularly the Limit of Detection (LOD), is not merely a technical metric but a pivotal determinant in clinical efficacy.

The fundamental challenge lies in the biological and technical factors that contribute to discordant results. Tumors may shed varying amounts of circulating tumor DNA (ctDNA) into the bloodstream, and spatial heterogeneity within tumors can lead to different genomic profiles in tissue samples versus circulating DNA [4] [52]. Advanced liquid biopsy assays with superior LOD can mitigate this discordance by detecting alterations present at low variant allele frequencies (VAFs), thereby providing a more comprehensive genomic profile to guide therapeutic decisions [64].

Key Performance Metrics in Analytical Validation

Defining Limit of Detection and Related Parameters

Analytical validation ensures that diagnostic tests reliably detect target analytes at the concentrations relevant to clinical decision-making. Several key parameters establish these performance characteristics:

• Limit of Blank (LOB): The highest apparent analyte concentration expected to be found in replicates of a blank sample containing no analyte. It represents the background noise of the assay system and is defined as LOB = Meanblank + 1.645 * SDblank (one-sided 95%) [65].
• Limit of Detection (LOD): The lowest analyte concentration that can be reliably distinguished from the LOB with 95% confidence. ICH Q2 guidelines define LOD as "the lowest amount of analyte in a sample which can be detected but not necessarily quantitated as an exact value" [65]. For quantitative assays with background noise, LOD is typically calculated as LOD = Meanblank + 3.3 * SDblank [65].
• Limit of Quantitation (LOQ): The lowest analyte concentration that can be quantitatively determined with acceptable precision and accuracy. LOQ is generally established at LOQ = Meanblank + 10 * SDblank [65].

These parameters are typically determined through serial dilution studies using samples with known analyte concentrations, with statistical approaches tailored to the assay methodology [65] [66].

Comprehensive Analytical Parameters Table

Beyond LOD, multiple analytical parameters must be validated to ensure assay reliability across intended use conditions:

Table 1: Essential Analytical Performance Parameters for IVD Devices

Parameter	Definition	Regulatory Importance	Common Assessment Method
Sensitivity	Ability to correctly identify true positives	Critical for disease detection	Comparison to reference standard
Specificity	Ability to correctly identify true negatives	Reduces false positives	Comparison to reference standard
Accuracy	Closeness of agreement between measured and true value	Fundamental test reliability	Testing against reference materials
Precision	Agreement between repeated measurements under specified conditions	Ensures result reproducibility	Within-run, between-run, between-day studies
Linearity	Ability to provide results proportional to analyte concentration	Validates quantitative range	Testing at multiple concentrations across claimed range
Analytical Specificity	Ability to measure solely the target analyte without interference	Ensures detection specificity	Testing with potentially interfering substances

Source: Adapted from SGS IVD Regulatory Webinar [66]

Comparative Performance of Liquid Biopsy Assays

Head-to-Head Validation Study Findings

A prospective comparative study evaluated the performance of BillionToOne's Northstar Select, a plasma-based comprehensive genomic profiling (CGP) assay, against six commercially available liquid biopsy assays from four CLIA/CAP laboratories [67] [64]. The assay covers 84 genes and detects SNV/Indels, CNVs, fusions, and microsatellite instability (MSI-H). The results demonstrated substantial performance differences between available technologies:

Table 2: Liquid Biopsy Assay Performance Comparison from Prospective Validation Study

Performance Metric	Northstar Select	Comparator Assays (Average)	Performance Improvement
LOD for SNV/Indels	0.15% VAF	Not reported	-
Pathogenic SNV/Indels Detected	51% more	Baseline	51% increase
Copy Number Variants Detected	109% more	Baseline	109% increase
Null Reports	45% fewer	Baseline	45% reduction
Actionable SNV/Indels Below 0.5% VAF	91% of additional findings	Limited detection	Significantly enhanced
CNV Detection Sensitivity	2.11 copies (amplifications), 1.80 copies (losses)	Limited detection	Enhanced CNV profiling
Fusion Detection LOD	0.30% VAF	Limited detection	Improved fusion identification

Source: BillionToOne Validation Study [64]

The dramatically improved detection rates, particularly for variants at low VAFs, directly address a key challenge in liquid biopsy: identifying actionable alterations in tumors with low ctDNA shedding [64]. This enhanced sensitivity has profound implications for clinical utility, as the ROME trial demonstrated that patients with alterations detected only in liquid biopsy (likely low-shedding cases) had significantly worse outcomes (median OS 4.05 months) compared to those with concordant tissue-liquid findings (median OS 11.05 months) [3].

LOD Comparison Across Technologies

The determination of LOD varies based on assay technology and regulatory approach:

Table 3: Methods for Determining Limit of Detection (LOD)

Method	Approach	Best Suited For	Statistical Foundation
Standard Deviation of Blank	Measures background noise in blank samples	Quantitative assays with minimal background noise	LOD = Meanblank + 3.3 * SDblank
Standard Deviation of Response & Slope	Uses calibration curve variability	Quantitative assays without significant background noise	LOD = 3.3σ/Slope
Signal-to-Noise Ratio	Compares analyte signal to background noise	Assays with measurable background noise	S/N ratio of 2-3:1 typically defines LOD
Visual Evaluation	Determines concentration where detection becomes reliable	Qualitative, visual, or identification assays	Logistics regression for probability of detection

Source: ICH Q2 Guidelines [65]

Experimental Protocols for LOD Determination

Protocol for LOD Validation Using Serial Dilutions

Robust LOD validation requires carefully controlled experiments with characterized reference materials:

• Sample Preparation: Create a dilution series from reference material with known variant allele frequency, spanning expected LOD concentrations. Include at least 5-7 concentration levels with 6-10 replicates each [65].

• Experimental Design: Process samples across multiple days, operators, and instruments to capture real-world variability. Include negative controls (blank samples) to establish baseline noise [65] [66].

• Data Analysis: For quantitative methods, use regression analysis of signal-to-noise ratio versus concentration. The LOD is typically identified where signal-to-noise ratio reaches 2:1 to 3:1 [65].

• Verification: Confirm LOD by testing 20-30 replicates at the determined LOD concentration; ≥95% should return positive results [66].

The Northstar Select validation followed this approach, using digital droplet PCR (ddPCR) confirmation to verify a 95% LOD of 0.15% VAF for SNV/Indels across 674 analytical patient samples representing various solid tumor types [64].

Workflow for Comprehensive Analytical Validation

The following diagram illustrates the complete analytical validation workflow for establishing LOD and related parameters:

Impact on Tissue-Liquid Biopsy Concordance

Analytical Factors in Biopsy Discordance

The ROME trial provided critical insights into discordance rates between tissue and liquid biopsy, with only 49% of cases showing concordant druggable alterations, while 35% had alterations exclusive to tissue, and 16% exclusive to liquid biopsy [3] [4]. This discordance stems from both biological and technical factors:

• Biological Factors: Tumor heterogeneity, differential ctDNA shedding, and temporal tumor evolution between sample collections [4] [52].
• Technical Factors: Variation in assay sensitivity, with lower LOD assays missing alterations present at low VAFs [64].

The clinical impact of this discordance is substantial. In the ROME trial, patients with concordant alterations receiving tailored therapy demonstrated significantly improved progression-free survival (median PFS 4.93 vs. 2.80 months; HR 0.55) compared to standard of care [3]. Conversely, the survival benefit was less pronounced in discordant cases, highlighting how detection limitations can directly impact therapeutic efficacy.

Pathway Analysis of Discordance Patterns

The ROME trial identified specific molecular pathways with high discordance rates, suggesting particular challenges in their detection:

The Scientist's Toolkit: Essential Research Reagents

Successful analytical validation requires carefully selected reagents and materials to ensure reproducible, reliable results:

Table 4: Essential Research Reagents for Liquid Biopsy Analytical Validation

Reagent/Material	Function	Critical Specifications	Example Applications
cfDNA Stabilization Tubes	Preserves cell-free DNA integrity during storage/transport	Stabilization time, inhibition of cellular genomic DNA contamination	Clinical sample collection for liquid biopsy [68]
Reference Standard Materials	Provides known variant allele frequencies for LOD studies	Certified variant percentages, matrix compatibility	LOD verification, assay calibration [65]
Digital Droplet PCR (ddPCR)	Independent verification of variant detection	Sensitivity, precision, quantitative accuracy	Confirmation of NGS-based LOD claims [64]
Negative Control Plasma	Establishes baseline background signal	Certified variant-free, appropriate matrix	Determining LOB, specificity measurements [65]
Next-Generation Sequencing Kits	Target capture and library preparation	Panel comprehensiveness, hybridization efficiency	Comprehensive genomic profiling [3] [64]

Thorough analytical validation establishing precise Limit of Detection parameters is fundamental to the reliability and clinical utility of liquid biopsy assays. As demonstrated in the ROME trial, the concordance between tissue and liquid biopsy findings has direct implications for patient survival outcomes in precision oncology [3] [4]. Advanced assays with improved LOD, such as Northstar Select with its 0.15% VAF sensitivity for SNV/Indels, demonstrate that technical enhancements can significantly increase detectable alterations (51% more pathogenic SNV/indels, 109% more CNVs) and reduce null reports by 45% [64].

The integration of both biopsy modalities, understanding their complementary strengths and limitations, and continuing advancement in detection technologies will further refine precision oncology approaches. As validation methodologies standardize and technologies evolve, the systematic establishment of analytical performance characteristics will remain the foundation for translating genomic findings into improved patient outcomes.

Precision oncology relies on accurate genomic profiling to match patients with effective targeted therapies. However, a key challenge lies in choosing the most reliable method for this profiling. The phase II ROME trial provides compelling evidence that the long-standing debate between using tissue or liquid biopsies may be missing the point. Its findings suggest that the true clinical benefit is unlocked when the same actionable genomic alteration is identified through both biopsy modalities, leading to significantly improved patient survival compared to standard of care.

Experimental Design and Methodologies

The ROME trial was a multicenter, randomized, open-label study designed to evaluate the efficacy of tailored therapy (TT) guided by comprehensive genomic profiling.

Patient Recruitment and Screening

Between November 2020 and August 2023, the trial screened 1,794 adult patients with advanced or metastatic solid tumors who had progressed after one or two lines of therapy [69]. A key eligibility requirement was the provision of samples for both liquid and tissue biopsy. Centralized next-generation sequencing (NGS) was then performed on both sample types using FoundationOne CDx for tissue and FoundationOne Liquid CDx for blood-derived circulating tumor DNA (ctDNA) [4] [69] [63].

Molecular Tumor Board and Randomization

A centralized Molecular Tumor Board (MTB) reviewed all sequencing results to identify actionable genomic alterations [3]. Actionability was determined based on the presence of biomarkers that could be targeted with drugs available within the trial framework.

• From the 1,794 screened patients, the MTB identified 400 patients with actionable alterations who were subsequently randomized to receive either TT or the investigator's choice of standard of care (SoC) [69].
• Randomization was stratified by cancer type into four cohorts: breast cancer, non-colorectal gastrointestinal cancer, non-small cell lung cancer (NSCLC), and other malignancies [69].

Defining Biopsy Concordance

A critical aspect of the ROME trial's exploratory analysis was the classification of patients based on biopsy results [4] [3]:

• Concordance: Detection of the same druggable genomic alteration in both the tissue and liquid biopsy.
• Discordance: Detection of an actionable alteration in only one biopsy type (either tissue or liquid).

Analysis of Discordance

For the 203 discordant cases, the investigators identified several primary causes [63]:

• Differences in molecular alteration detection (43.3%)
• Discordant high tumor mutational burden (hTMB) (35%)
• Test failures (21%)
• Microsatellite instability (MSI) discrepancies (1%) The PI3K/PTEN/AKT/mTOR and ERBB2 pathways exhibited the highest rates of discordance [63].

Key Findings and Survival Outcomes

The ROME trial demonstrated that tailored therapy significantly improved outcomes, with the most profound benefits observed in patients with concordant biopsy results.

Efficacy in the Intention-to-Treat Population

In the overall randomized population of 400 patients, TT showed a statistically significant improvement in the primary endpoint, the Overall Response Rate (ORR), and in key secondary endpoints [69]:

• ORR was 17.5% in the TT arm versus 10% in the SoC arm (P = 0.0294).
• Median Progression-Free Survival (PFS) was 3.5 months with TT versus 2.8 months with SoC (HR = 0.66; P = 0.0002).

Superior Outcomes with Biopsy Concordance

The most striking results emerged from the analysis of the 197 patients where the same alteration was found in both tissue and liquid biopsies (the T+L group). The table below summarizes the survival outcomes for the concordant group receiving TT versus SoC.

Table 1: Survival Outcomes in the Concordant (T+L) Patient Group

Outcome Measure	Tailored Therapy (T+L)	Standard of Care (SoC)	Hazard Ratio (HR)
Median Overall Survival (OS)	11.05 months	7.70 months	0.74 (95% CI: 0.51-1.07) [4] [3]
12-Month OS Rate	47.8%	38.8%	Not Provided
Median Progression-Free Survival (PFS)	4.93 months	2.80 months	0.55 (95% CI: 0.40-0.76) [4] [3]
12-Month PFS Rate	27.2%	9.1%	Not Provided
Objective Response Rate (ORR)	20.0%	11.8%	Not Provided

Outcomes in Discordant Populations

The benefit of TT was markedly less pronounced when the actionable alteration was identified in only one biopsy type. The following table compares the outcomes across different biopsy result categories, highlighting the central role of concordance.

Table 2: Outcomes by Biopsy Result Category in the ROME Trial

Biopsy Result Category	Prevalence in Randomized Patients	Median OS with TT	Median PFS with TT
Concordant (T+L)	49.2% (197 patients)	11.05 months	4.93 months
Tissue-Only	34.7% (139 patients)	9.93 months	3.06 months
Liquid-Only	16.0% (64 patients)	4.05 months	2.07 months

These findings underscore that concordance between tissue and liquid biopsies serves as a powerful biomarker for identifying patients who are most likely to derive a substantial survival benefit from genomically guided therapy [3].

Signaling Pathways and Diagnostic Workflow

Pathways with High Discordance

As noted, the PI3K/PTEN/AKT/mTOR and ERBB2 (HER2) pathways were major sources of discordant results [63]. These pathways are critical in cell growth, proliferation, and survival, and are common targets in precision oncology. The diagram below illustrates the logical workflow for biopsy integration and the specific pathways where discordance often occurs.

Essential Research Reagent Solutions

The ROME trial relied on a suite of standardized reagents and platforms to ensure consistent and reliable genomic profiling across multiple clinical centers. The following table details key materials and their functions as used in the trial.

Table 3: Key Research Reagents and Platforms in the ROME Trial

Reagent / Platform	Function in the Experimental Workflow
FoundationOne CDx	Comprehensive genomic profiling of formalin-fixed paraffin-embedded (FFPE) tissue samples via NGS [69].
FoundationOne Liquid CDx	Comprehensive genomic profiling of cell-free DNA (cfDNA) from blood plasma (liquid biopsy) via NGS [69].
Streck Cell-Free DNA BCT Tubes	Blood collection tubes that stabilize nucleated blood cells to prevent genomic DNA contamination of plasma cfDNA [70].
Molecular Tumor Board (MTB)	A multidisciplinary expert panel that interprets complex genomic data and recommends tailored therapies based on actionability [69].

The ROME trial provides a clear and practice-informing advance: it demonstrates that concordance between tissue and liquid biopsies is a robust biomarker for optimizing patient selection for tailored therapy. Patients whose actionable alterations were confirmed in both modalities experienced significantly improved survival, with a 45% reduction in the risk of progression and a 26% reduction in the risk of death [4] [3]. This evidence strongly supports the integration of both tissue and liquid biopsy into a new standard diagnostic pathway for advanced solid tumors, moving beyond the paradigm of using either test alone. For researchers and drug developers, these findings highlight the necessity of designing future clinical trials and diagnostic algorithms to leverage the complementary strengths of both biopsy methods to enhance clinical outcomes in precision oncology.

In the era of precision oncology, comprehensive genomic profiling has become indispensable for guiding therapeutic decisions. For years, tissue biopsy has been the gold standard for molecular characterization of tumors, providing a direct snapshot of the tumor's genetic landscape [6]. However, the emergence of liquid biopsy—a minimally invasive technique analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers in blood—has introduced a paradigm shift in cancer diagnostics [71]. This comparative analysis examines the relative merits, limitations, and clinical applications of tissue biopsy, liquid biopsy, and their combined use, with particular focus on their concordance levels and implications for treatment outcomes within advanced solid tumors.

The fundamental distinction between these approaches lies in their source material and inherent capabilities. Tissue biopsies provide a structural and molecular view of a specific tumor site but are constrained by tumor heterogeneity and invasiveness [72]. Liquid biopsies offer a systemic, real-time view of tumor dynamics through a simple blood draw, capturing contributions from multiple tumor sites, but face challenges related to sensitivity limitations in low-shedding tumors [26] [73]. Understanding the balance between these modalities is critical for optimizing cancer diagnostic pathways.

Performance Metrics and Clinical Concordance

Direct Comparison of Key Performance Indicators

Extensive clinical studies have quantified the performance differences between tissue and liquid biopsy approaches across multiple dimensions, from turnaround time to biomarker detection rates.

Table 1: Performance comparison between tissue and liquid biopsy

Performance Metric	Tissue Biopsy	Liquid Biopsy	Clinical Implications
Turnaround Time (TAT)	36.4 days [74]	9.6 days [74]	Faster treatment initiation with liquid biopsy
Testing Success Rate	Variable; limited by tissue adequacy [72]	Higher success rate reported [74]	Reduced need for repeat procedures with liquid biopsy
Guideline-Recommended Biomarker Detection	54.9% (tissue-first approach) [74]	76.5% (liquid-first approach) [74]	Improved biomarker identification with liquid-first strategy
Concordance for Actionable Biomarkers	Reference standard	94.8%-100% [74]	High reliability enables liquid biopsy for treatment decisions
Sensitivity for CNVs/Rearrangements	High	Reduced; technological challenge [73]	Tissue superiority for detecting copy number variations
Invasiveness/Procedural Risk	High (surgical risk) [72]	Minimal (blood draw) [26]	Liquid enables serial monitoring; better patient tolerance

Concordance Data and Impact on Therapeutic Outcomes

The concordance between tissue and liquid biopsy findings has direct implications for treatment efficacy. Data from the ROME trial, a phase II multicenter study involving 1,794 patients with advanced solid tumors, provides critical insights into how concordance influences survival outcomes.

Table 2: Impact of biopsy concordance on survival outcomes based on ROME trial data

Biopsy Concordance Group	Median Overall Survival (Months)	Median Progression-Free Survival (Months)	Benefit from Tailored Therapy
Concordant (Tissue + Liquid)	11.05 [3]	4.93 [3]	Significant improvement
Tissue-Only Detection	9.93 [3]	3.06 [3]	Moderate benefit
Liquid-Only Detection	4.05 [3]	2.07 [3]	Minimal to no benefit
Overall Population	7.70 (SoC) vs. 11.05 (TT) [3]	2.80 (SoC) vs. 4.93 (TT) [3]	Significant improvement with tailored therapy

The ROME trial demonstrated that patients with concordant results who received tailored therapy experienced substantially improved survival outcomes compared to standard of care (median OS 11.05 vs. 7.70 months; HR 0.74) [3]. This superior performance in the concordant group underscores the complementary value of both modalities in capturing a complete genomic picture for optimal therapeutic decision-making.

Analytical Methodologies and Technical Considerations

Experimental Protocols for Concordance Studies

Methodologies for direct comparison studies typically involve parallel testing of matched tissue and blood samples from the same patients, with rigorous statistical analysis of agreement rates.

Sample Collection and Processing Protocols:

• Tissue Biopsy: Formalin-fixed paraffin-embedded (FFPE) tissue sections with minimum tumor cellularity requirements (typically >20%) [73]. DNA extraction yields must meet minimum thresholds for library preparation.
• Liquid Biopsy: Whole blood collection in specialized stabilization tubes (e.g., Streck Cell-Free DNA BCT), followed by double centrifugation to isolate platelet-poor plasma [73]. Cell-free DNA extraction typically utilizes silica-based membrane methods.

Sequencing and Analysis Methods:

• Next-Generation Sequencing (NGS): Both tissue and liquid biopsies employ hybrid capture-based NGS panels covering relevant cancer genes [73]. For tissue, FoundationOneCDx analyzes 324 genes; for liquid, FoundationOneLiquid CDx covers 311 genes [73].
• Tumor Fraction Estimation: In liquid biopsies, ctDNA tumor fraction is estimated using copy number alteration patterns or variant allele frequencies of somatic mutations [73]. This parameter critically influences detection sensitivity.
• Concordance Calculation: Positive percent agreement (PPA) is calculated as (Number of alterations detected in both/(Number detected in tissue)) × 100, with tissue as reference [73].

Technological Advancements in Liquid Biopsy Sensitivity

Recent technological innovations have substantially improved liquid biopsy performance, particularly for low-shedding tumors. The development of Northstar Select, a plasma-based comprehensive genomic profiling assay covering 84 genes, demonstrates significantly enhanced sensitivity compared to earlier platforms [64] [75].

Key advancements include:

• Improved Limit of Detection: 95% LOD of 0.15% variant allele frequency for SNV/Indels, compared to approximately 0.5% VAF for earlier assays [64].
• Enhanced CNV Detection: Sensitive detection of copy number variations down to 2.11 copies for amplifications and 1.80 copies for losses [64].
• Reduced Null Reports: 45% fewer null reports (no pathogenic or actionable results) compared to existing commercial assays [64].

These technical improvements have particular clinical importance for detecting actionable mutations in tumors with low ctDNA shedding, potentially expanding the applications of liquid biopsy in early-stage disease and minimal residual disease monitoring.

Visualizing Biopsy Concordance and Clinical Implementation

Tumor Heterogeneity and Biopsy Sampling Concepts

The following diagram illustrates how tissue and liquid biopsies capture different aspects of tumor biology and heterogeneity, which underpins both their complementary value and the observed discordance in some cases.

Tumor Heterogeneity Sampling Diagram

This visualization demonstrates key concepts: tissue biopsy captures genetic information from a specific site (potentially missing spatial heterogeneity), while liquid biopsy captures ctDNA shed from all tumor sites into the bloodstream, providing a more comprehensive representation of the overall tumor burden and heterogeneity [72].

Clinical Decision Pathways for Biomarker Testing

The following workflow diagram outlines an evidence-based approach for implementing combined profiling in clinical practice, based on concordance research findings.

Clinical Implementation Pathway

This evidence-based pathway reflects findings that a "liquid-first" approach identifies guideline-recommended biomarkers in 76.5% of patients versus 54.9% in a "tissue-first" approach [74], while maintaining the option for tissue reflex in negative cases, particularly when tumor fraction is low (<1%) [73].

Essential Research Reagents and Platforms

The following table catalogues key experimental tools and platforms referenced in concordance studies, providing researchers with essential technical specifications for experimental design.

Table 3: Key research reagents and platforms for biopsy concordance studies

Research Tool	Type/Platform	Key Specifications	Primary Applications
FoundationOneCDx	Tissue-based NGS	324 genes; SNVs, Indels, CNVs, fusions [73]	Comprehensive tissue genomic profiling; companion diagnostic
FoundationOneLiquid CDx	Liquid-based NGS	311 genes; SNVs, Indels, CNVs, fusions [73]	Blood-based genomic profiling; companion diagnostic
Northstar Select	Liquid-based CGP	84 genes; LOD: 0.15% VAF (SNV/Indels) [64]	High-sensitivity ctDNA detection; low-shedding tumors
CellSearch System	CTC Enumeration	FDA-cleared for CTC counting [6]	Prognostic assessment; metastasis research
Streck Cell-Free DNA BCT	Blood Collection Tube	Preserves ctDNA integrity [73]	Standardized pre-analytical ctDNA stabilization

These tools represent the current technological standards in biopsy comparative research, with each platform having distinct strengths in specific applications. The selection of appropriate platforms is critical for generating clinically actionable data in concordance studies.

Discussion and Clinical Implications

Interpretation of Concordance Data

The observed 49% concordance rate between tissue and liquid biopsies for actionable mutations in the ROME trial, with alterations detected exclusively in tissue (35%) or liquid (16%) in the remaining cases, highlights the complementary nature of these approaches [3]. This partial overlap stems from biological and technical factors including spatial heterogeneity, temporal heterogeneity (especially after treatment), differential shedding patterns, and varying analytical sensitivities across platforms.

The superior outcomes in patients with concordant findings likely reflect several advantages: (1) validation of key driver mutations through dual confirmation, (2) more comprehensive tumor profiling capturing both clonal and subclonal alterations, and (3) identification of a more stable genomic profile less susceptible to sampling bias. The significantly reduced benefit in the "liquid-only" group (median OS: 4.05 months) may indicate challenging disease biology with low tumor shedding or predominantly sanctuary site metastases not adequately captured in circulation [3].

Optimal Integration in Clinical Practice and Research

Based on current evidence, a combined profiling approach maximizes clinical utility while acknowledging practical constraints. The recommended implementation strategy includes:

• Liquid-First Testing: For most advanced cancers, initial liquid biopsy provides rapid results (9.6 days vs. 36.4 days for tissue) [74] with high concordance for guideline-recommended biomarkers (94.8%-100%) [74], enabling faster treatment initiation.
• Reflex to Tissue: When liquid biopsy is negative or yields insufficient ctDNA (tumor fraction <1%), tissue biopsy should follow, particularly for detection of CNVs and rearrangements where tissue outperforms liquid [73].
• Molecular Tumor Board Review: Combined results should be reviewed multidisciplinary to prioritize potentially conflicting findings and optimize therapeutic recommendations [3].

For clinical trial design, these findings support the incorporation of both modalities for patient stratification, particularly in biomarker-driven studies. The differential outcomes based on concordance status suggest that this parameter may serve as an important stratification factor in future trials.

Tissue biopsy, liquid biopsy, and combined profiling each offer distinct advantages and limitations in genomic characterization of tumors. While liquid biopsy demonstrates superior turnaround time and comparable accuracy for many actionable biomarkers, tissue biopsy remains essential for detecting certain alteration types and in cases of low ctDNA shedding. The combined approach maximizes biomarker detection rates and, most importantly, identifies the patient population most likely to benefit from tailored therapies—those with concordant findings between both modalities.

Future directions in the field include the development of even more sensitive liquid biopsy assays, standardized protocols for combined profiling interpretation, and refined clinical pathways that leverage the complementary strengths of both approaches. As technological advancements continue to address current limitations, the integration of multi-modal genomic profiling will undoubtedly become more streamlined, ultimately advancing the goal of personalized precision oncology through comprehensive tumor characterization.

In precision oncology, the identification of actionable genomic alterations traditionally relies on tissue biopsy. However, tumor heterogeneity, procedural invasiveness, and technical limitations can restrict its comprehensive profiling capabilities. Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) and other biomarkers from blood, presents a less invasive alternative but may not detect all alterations. The concordance between these two methods—defined as the detection of the same significant genomic alterations in both sample types—has emerged as a critical factor with significant prognostic implications for overall survival (OS) and progression-free survival (PFS) in patients with advanced solid tumors.

Quantitative Evidence: Survival Outcomes by Biopsy Concordance

Recent clinical studies provide compelling quantitative evidence that patients whose treatments are guided by actionable alterations found in both tissue and liquid biopsies experience superior survival outcomes compared to those with discordant results or those receiving standard of care.

Table 1: Survival Outcomes from the ROME Trial (Phase II) by Biopsy Result Group [63] [4]

Biopsy Result Group	Tailored Therapy Median OS (months)	Standard-of-Care Median OS (months)	Tailored Therapy Median PFS (months)	Standard-of-Care Median PFS (months)
Tissue + Liquid (Concordant)	11.1	7.7	4.9	2.8
Tissue-Only (Discordant)	9.9	Not Reported	3.1	Not Reported
Liquid-Only (Discordant)	4.1	Not Reported	2.1	Not Reported

The ROME trial demonstrated that for patients in the concordant group, tailored therapy based on dual-positive findings led to a 26% reduction in the risk of death and a 45% reduction in the risk of disease progression compared to standard of care [63] [4].

Table 2: Concordance and Discordance Rates of Actionable Alterations in the ROME Trial [63] [4]

Category	Rate	Primary Contributing Factors
Overall Concordance	49%	Detection of same alterations in both biopsies
Tissue-Only Alterations	35%	Test failures; Tumor not shedding ctDNA; Limitations in biopsy site
Liquid-Only Alterations	16%	Differences in molecular alteration detection; Discordant TMB detection

The prognostic strength of concordance is further supported by findings in specific cancers. In a study of advanced biliary tract cancer, ctDNA-based genotyping showed an 84.8% sensitivity and 79.4% positive predictive value for detecting tissue-based mutations. A high variant allele frequency in ctDNA was strongly associated with poorer OS and PFS following chemotherapy [76].

Experimental Protocols and Methodologies

The ROME Trial Protocol

The phase II ROME trial provides a robust methodological framework for assessing the prognostic value of biopsy concordance [63] [4].

• Patient Cohort: The study enrolled 1,794 patients with advanced solid tumors who had received their second- or third-line treatment.
• Sample Collection: Both tissue and liquid biopsy samples were collected from all participants. The timing of sample acquisition is a noted consideration, as tissue and liquid biopsies were not always simultaneous.
• Genomic Profiling: Centralized next-generation sequencing (NGS) was performed using the FoundationOne CDx assay for tissue and the FoundationOne Liquid CDx assay for plasma ctDNA.
• Analysis and Actionability: A centralized molecular tumor board reviewed the sequencing results to identify actionable genomic alterations. Patients with such alterations (n=400) were categorized into three groups: T+L (concordant), Tissue-Only, or Liquid-Only.
• Treatment and Endpoints: Patients within each group were randomized to receive either tailored therapy targeting the identified alteration or standard-of-care treatment. The primary endpoints were OS and PFS, which were analyzed across the different concordance groups.

Prognostic Model Development

Beyond clinical trials, the development of validated prognostic models is essential for stratifying patient risk. One established statistical method involves:

• LASSO Regression: A technique used to select the most relevant prognostic variables from a large dataset while preventing overfitting [77].
• Nomogram Development: The selected variables are used to construct a nomogram, which is a graphical calculation tool that predicts the probability of a clinical event, such as survival, for an individual patient [77] [78].
• Validation: The model's performance is evaluated using metrics like the Concordance Index (C-index), which measures how well the model predicts the order of events in time-to-event data. A higher C-index indicates better predictive accuracy. The model is then validated in a separate patient cohort to ensure its reliability [77] [78].

Visualizing Diagnostic Pathways and Prognostic Strength

The following diagram illustrates the diagnostic pathway for precision oncology and how biopsy concordance influences prognostic strength and subsequent treatment decisions.

Key Signaling Pathways with High Discordance

Research from the ROME trial identified specific oncogenic pathways with notably high rates of discordance between tissue and liquid biopsy methods [63] [4]. Investigating these pathways is crucial for understanding the biological underpinnings of discordant results.

• PI3K/PTEN/AKT/mTOR Pathway: This is a critical intracellular signaling pathway that regulates cell cycle, growth, and survival. Discordance here may arise from spatial heterogeneity within the tumor or technical challenges in detecting specific types of alterations in ctDNA.
• ERBB2 (HER2) Pathway: ERBB2 is a receptor tyrosine kinase whose amplification or overexpression is a key driver in certain cancers. Discordance in its detection could significantly impact the selection of HER2-targeted therapies.

The Scientist's Toolkit: Essential Research Reagents and Materials

Successful research in this field relies on a suite of specialized reagents and platforms for genomic analysis and biomarker validation.

Table 3: Key Research Reagent Solutions for Concordance Studies [63] [76] [6]

Reagent/Material	Function in Research	Specific Examples
NGS Assays for Tissue	Comprehensive genomic profiling of formalin-fixed paraffin-embedded (FFPE) tissue samples to identify mutations, TMB, and MSI.	FoundationOne CDx
NGS Assays for Liquid Biopsy	Targeted or comprehensive profiling of ctDNA from blood plasma to detect tumor-derived genomic alterations.	FoundationOne Liquid CDx, AlphaLiquid100
CTC Enrichment & Detection Kits	Isolation and enumeration of circulating tumor cells from peripheral blood for prognostic studies.	CellSearch system (FDA-cleared)
cfDNA Extraction Kits	High-quality, rapid extraction of cell-free DNA from blood plasma, crucial for downstream NGS analysis.	Kits from QIAGEN, Roche
PCR/Kits for Biomarker Validation	Analytical validation of specific mutations identified by NGS; used for bridging studies and assay verification.	Digital PCR (dPCR) systems

The convergence of evidence firmly establishes that concordance between tissue and liquid biopsies is a powerful prognostic indicator, with patients exhibiting concordant actionable alterations deriving the greatest survival benefit from tailored therapies. While the ROME trial reports a 49% concordance rate, the integration of both methods increases the detection of actionable alterations by over 60% compared to either method alone [63] [4]. This underscores the complementary nature of these biopsy modalities. Future research must focus on standardizing methodologies, understanding the biological basis of discordance in key pathways, and validating these findings in larger, prospective multicenter cohorts. For researchers and drug developers, a dual-biopsy strategy is not merely an option but appears essential for optimizing patient selection and advancing the field of precision oncology.

Conclusion

The evidence firmly establishes that tissue and liquid biopsies are complementary, not competing, technologies in precision oncology. High concordance is achievable and is associated with significantly improved patient survival outcomes, as demonstrated by trials like ROME. However, biological and technical discordance remains a challenge, particularly in low-shedding tumors and specific molecular pathways. Future directions for research and drug development must focus on standardizing methodologies, enhancing assay sensitivity for low-frequency variants, and validating the clinical utility of combined profiling in larger, prospective trials. Integrating serial liquid biopsies with initial tissue profiling will be crucial for monitoring clonal evolution and therapy resistance, ultimately paving the way for more dynamic and effective personalized cancer treatments.

References

• 1. Sensitivity, Specificity, Positive Predictive Value, and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8156826/]
• 2. Sensitivity, Specificity, Positive Predictive Value… Oh My! [https://srhd.org/blogs/2018/sensitivity-specificity-positive-predictive-value-oh-my]
• 3. The Impact of Concordance Between Liquid and Tissue ... [https://pubmed.ncbi.nlm.nih.gov/40833744/]
• 4. Patient Outcomes May Improve With Tailored Treatment ... [https://www.aacr.org/about-the-aacr/newsroom/news-releases/patient-outcomes-may-improve-with-tailored-treatment-guided-by-tissue-plus-liquid-biopsies-vs-individually/]
• 5. Liquid Biopsy Versus Tissue Biopsy to Determine Front ... [https://pubmed.ncbi.nlm.nih.gov/36585341/]
• 6. Liquid biopsy in cancer: current status, challenges and ... [https://www.nature.com/articles/s41392-024-02021-w]
• 7. A Tale of Two Biopsies: Liquid Biopsy vs Tissue Biopsy [https://www.biochain.com/blog/a-tale-of-two-biopsies-liquid-biopsy-vs-tissue-biopsy/]
• 8. Tumor Heterogeneity, Clonal Evolution, and Therapy Resistance [https://pmc.ncbi.nlm.nih.gov/articles/PMC4083486/]
• 9. Clonal Heterogeneity and Tumor Evolution: Past, Present ... [https://www.sciencedirect.com/science/article/pii/S0092867417300661]
• 10. 【前沿进展】液体活检用于EGFR突变检测一致性为94.5% [http://www.liangyihui.net/doc/124847]
• 11. Research Progress on the Application of Liquid Biopsy in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9411954/]
• 12. Research progress on circulating tumor DNA as a biomarker ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10621050/]
• 13. Research progress of CTC, ctDNA, and EVs in cancer liquid ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10850354/]
• 14. Cancer in a Drop: Liquid biopsy insights from AACR 2025 [https://pmc.ncbi.nlm.nih.gov/articles/PMC12223554/]
• 15. Advances in CTC and ctDNA detection techniques [https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-025-02024-7]
• 16. Liquid biopsy of circulating tumor cells: From isolation ... [https://pubmed.ncbi.nlm.nih.gov/40331286/]
• 17. Dual Biomarker Strategies for Liquid Biopsy: Integrating ... [https://www.mdpi.com/2079-6374/15/2/74]
• 18. Liquid biopsy based on EV biomarkers: A new frontier for ... [https://www.sciencedirect.com/science/article/pii/S2790676025000159]
• 19. On the dilemma of using single EV analysis for liquid biopsy [https://pubmed.ncbi.nlm.nih.gov/40860141/]
• 20. Improvement of the sensitivity of circulating tumor DNA-based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12332530/]
• 21. Survival Outcomes May Improve When Treatment Is ... [https://ascopost.com/news/april-2025/survival-outcomes-may-improve-when-treatment-is-guided-by-using-both-tissue-and-liquid-biopsies/]
• 22. Analytical Concordance of PD-L1 Assays Utilizing Antibodies ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8202559/]
• 23. Concordance study of PD-L1 expression in primary and ... [https://www.nature.com/articles/modpathol2017188]
• 24. Diagnostic Performance of Liquid Biopsy Compared to ... [https://jchr.org/index.php/JCHR/article/view/10903]
• 25. The Impact on the Therapeutic Decision of Massive Gene ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12611080/]
• 26. Liquid biopsy – a narrative review with an update on current ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12333414/]
• 27. Implementing liquid biopsy NGS in stage III/IV NSCLC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12619507/]
• 28. Diagnostic accuracy of next-generation sequencing (NGS) ... [https://link.springer.com/article/10.1007/s12094-025-04040-7]
• 29. Next generation DNA Sequencing data analysis and its ... [https://www.sciencedirect.com/science/article/abs/pii/S034403382500473X]
• 30. Comparative assessment of the Sikun 2000 sequencing ... [https://www.nature.com/articles/s41598-025-04170-6]
• 31. Next-generation sequencing: 2025 Revolution [https://lifebit.ai/blog/next-generation-sequencing/]
• 32. Liquid biopsy in cancer management: Integrating diagnostics ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11743551/]
• 33. Liquid Biopsy to Detect Minimal Residual Disease [https://pmc.ncbi.nlm.nih.gov/articles/PMC8582541/]
• 34. Liquid biopsy for monitoring minimal residual disease in ... [https://www.sciencedirect.com/science/article/pii/S2950195424000109]
• 35. Expanding Horizons in Cholangiocarcinoma: Emerging ... [https://www.mdpi.com/1422-0067/26/21/10755]
• 36. Co-clinical trial targeting ER, FGFR and CDK4/6 in resistant ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12594994/]
• 37. Disease characteristics and monitoring of IDH1/IDH2 ... [https://www.nature.com/articles/s41408-025-01304-x]
• 38. Advances and challenges in targeted therapies for HER2- ... [https://www.sciencedirect.com/science/article/pii/S0959804925002527]
• 39. KRAS G12C Inhibition in Solid Tumors - PubMed Central - NIH [https://pmc.ncbi.nlm.nih.gov/articles/PMC12427421/]
• 40. The Landscape of Genomic Alterations in Receptor Tyrosine ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12535519/]
• 41. Mutational Landscape Assessed in Tumor Tissue and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12330086/]
• 42. Data mining and safety analysis of FGFR tyrosine kinase ... [https://www.nature.com/articles/s41598-025-11411-1]
• 43. Liquid-based CGP is critical for matching cancer patients to ... [https://www.illumina.com/content/illumina-marketing/amr/en_US/company/news-center/feature-articles/asco-2025-abstract-ctdna.html]
• 44. Extending the clinical indications of liquid biopsy: plasma ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12432645/]
• 45. Liquid Biopsy Market Size to Surpass USD 22.69 Billion ... [https://www.biospace.com/press-releases/liquid-biopsy-market-size-to-surpass-usd-22-69-billion-by-2034-driven-by-early-cancer-detection-and-precision-diagnostics]
• 46. Identification of major factors associated with failed clinical molecular... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5528718/]
• 47. (PDF) Tissue is alive: New technologies are needed to address the... [https://www.academia.edu/4399444/Tissue_is_alive_New_technologies_are_needed_to_address_the_problems_of_protein_biomarker_pre_analytical_variability]
• 48. Frequency of Technical Errors in the Biopsy Samples ... [https://jrdms.dentaliau.ac.ir/browse.php?a_id=159&sid=1&slc_lang=en&html=1]
• 49. Leading Causes of Diagnostic Errors in U.S. Healthcare ... [https://clpmag.com/resource-center/research/new-data-reveals-leading-causes-of-diagnostic-errors-in-u-s-healthcare/]
• 50. Liquid Biopsy: Promises and Problems | AACR Blog [https://www.aacr.org/blog/2018/08/03/liquid-biopsy-promises-and-problems/]
• 51. Recent Advances in Liquid Biopsy in Precision Oncology ... [https://pubmed.ncbi.nlm.nih.gov/30828064/]
• 52. AACR 2025: Tailored Treatment Guided by Combined ... [https://www.pharmacytimes.com/view/tailored-treatment-guided-by-combined-tissue-and-liquid-biopsies-may-improve-outcomes-in-advanced-solid-tumors]
• 53. PI3K/AKT/mTOR pathway - Wikipedia [https://en.wikipedia.org/wiki/PI3K/AKT/mTOR_pathway]
• 54. Expert Consensus on the Clinical Application of PI / 3 / K ... AKT mTOR [https://pmc.ncbi.nlm.nih.gov/articles/PMC11981814/]
• 55. AACR Results Seek Solutions to Precision Medicine Challenges | AJMC [https://www.ajmc.com/view/aacr-results-seek-solutions-to-precision-medicine-challenges]
• 56. Increased ErbB2 Signaling Is an Early Adaptation to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12580767/]
• 57. Validation of a liquid biopsy assay with increased sensitivity ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12447423/]
• 58. Prevalence and detection of low-allele-fraction variants in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5680209/]
• 59. Analytical Validation of a Pan-Cancer NGS Assay for In- ... [https://www.sciencedirect.com/science/article/pii/S152515782500220X]
• 60. A targeted next-generation sequencing panel for ... [https://www.nature.com/articles/s41598-025-08039-6]
• 61. Performance of Common Analysis Methods for Detecting ... [https://www.sciencedirect.com/science/article/pii/S1525157813002109]
• 62. Comparison of solid tissue sequencing and liquid biopsy ... [https://www.sciencedirect.com/science/article/pii/S0893395222003775]
• 63. Survival Outcomes May Improve When Treatment Is ... [https://ascopost.com/news/april-2025/survival-outcomes-may-improve-when-treatment-is-guided-by-using-both-tissue-and-liquid-biopsies]
• 64. Validation of a liquid biopsy assay with increased ... [https://www.sciencedirect.com/science/article/pii/S2950195425000384]
• 65. Method Validation Essentials, Limit of Blank ... [https://www.biopharminternational.com/view/method-validation-essentials-limit-blank-limit-detection-and-limit-quantitation]
• 66. Demonstrating Analytical Performance of IVD Devices [https://www.sgs.com/en-us/webinars/2025/11/demonstrating-analytical-performance-of-ivd-devices]
• 67. Liquid Biopsy | September Round-Up 2025 [https://www.decibio.com/insights/liquid-biopsy-september-round-up-2025]
• 68. Liquid Biopsy Tube Market Uplift USD 1.54 Billion in 2025 [https://www.towardshealthcare.com/insights/liquid-biopsy-tube-market-sizing]
• 69. Genomically matched therapy in advanced solid tumors [https://www.nature.com/articles/s41591-025-03918-x]
• 70. Mutational profiling using liquid biopsy to guide targeted ... [https://www.nature.com/articles/s41598-025-88094-1]
• 71. The growing field of liquid biopsy and its Snowball effect on ... [https://www.sciencedirect.com/science/article/pii/S2950195425000098]
• 72. Pros: Can tissue biopsy be replaced by liquid biopsy? - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC5009092/]
• 73. Retrospective comparison between breast cancer tissue [https://pmc.ncbi.nlm.nih.gov/articles/PMC12217283/]
• 74. Liquid Biopsy Versus Tissue Biopsy to Determine Front ... [https://www.sciencedirect.com/science/article/abs/pii/S1525730422002650]
• 75. Validation of a liquid biopsy assay with increased ... [https://pubmed.ncbi.nlm.nih.gov/40980342/]
• 76. Concordance of ctDNA and tissue genomic profiling in ... [https://pubmed.ncbi.nlm.nih.gov/39442892/]
• 77. A new prognostic model for predicting overall survival and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11752828/]
• 78. Prognostic nomogram that predicts progression-free ... [https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.956380/full]